for Journals by Title or ISSN
for Articles by Keywords
help

Publisher: Oxford University Press   (Total: 406 journals)

 A  B  C  D  E  F  G  H  I  J  K  L  M  N  O  P  Q  R  S  T  U  V  W  X  Y  Z  

        1 2 3 | Last   [Sort by number of followers]   [Restore default list]

Showing 1 - 200 of 406 Journals sorted alphabetically
ACS Symposium Series     Full-text available via subscription   (SJR: 0.189, CiteScore: 0)
Acta Biochimica et Biophysica Sinica     Hybrid Journal   (Followers: 5, SJR: 0.79, CiteScore: 2)
Adaptation     Hybrid Journal   (Followers: 9, SJR: 0.143, CiteScore: 0)
Advances in Nutrition     Hybrid Journal   (Followers: 53, SJR: 2.196, CiteScore: 5)
Aesthetic Surgery J.     Hybrid Journal   (Followers: 6, SJR: 1.434, CiteScore: 1)
Aesthetic Surgery J. Open Forum     Open Access  
African Affairs     Hybrid Journal   (Followers: 66, SJR: 1.869, CiteScore: 2)
Age and Ageing     Hybrid Journal   (Followers: 90, SJR: 1.989, CiteScore: 4)
Alcohol and Alcoholism     Hybrid Journal   (Followers: 19, SJR: 1.376, CiteScore: 3)
American Entomologist     Full-text available via subscription   (Followers: 8)
American Historical Review     Hybrid Journal   (Followers: 169, SJR: 0.467, CiteScore: 1)
American J. of Agricultural Economics     Hybrid Journal   (Followers: 44, SJR: 2.113, CiteScore: 3)
American J. of Clinical Nutrition     Hybrid Journal   (Followers: 174, SJR: 3.438, CiteScore: 6)
American J. of Epidemiology     Hybrid Journal   (Followers: 198, SJR: 2.713, CiteScore: 3)
American J. of Health-System Pharmacy     Full-text available via subscription   (Followers: 52, SJR: 0.595, CiteScore: 1)
American J. of Hypertension     Hybrid Journal   (Followers: 25, SJR: 1.322, CiteScore: 3)
American J. of Jurisprudence     Hybrid Journal   (Followers: 19, SJR: 0.281, CiteScore: 1)
American J. of Legal History     Full-text available via subscription   (Followers: 9, SJR: 0.116, CiteScore: 0)
American Law and Economics Review     Hybrid Journal   (Followers: 27, SJR: 1.053, CiteScore: 1)
American Literary History     Hybrid Journal   (Followers: 16, SJR: 0.391, CiteScore: 0)
Analysis     Hybrid Journal   (Followers: 22, SJR: 1.038, CiteScore: 1)
Animal Frontiers     Hybrid Journal   (Followers: 1)
Annals of Behavioral Medicine     Hybrid Journal   (Followers: 16, SJR: 1.423, CiteScore: 3)
Annals of Botany     Hybrid Journal   (Followers: 38, SJR: 1.721, CiteScore: 4)
Annals of Oncology     Hybrid Journal   (Followers: 56, SJR: 5.599, CiteScore: 9)
Annals of the Entomological Society of America     Full-text available via subscription   (Followers: 10, SJR: 0.722, CiteScore: 1)
Annals of Work Exposures and Health     Hybrid Journal   (Followers: 34, SJR: 0.728, CiteScore: 2)
Antibody Therapeutics     Open Access  
AoB Plants     Open Access   (Followers: 4, SJR: 1.28, CiteScore: 3)
Applied Economic Perspectives and Policy     Hybrid Journal   (Followers: 17, SJR: 0.858, CiteScore: 2)
Applied Linguistics     Hybrid Journal   (Followers: 59, SJR: 2.987, CiteScore: 3)
Applied Mathematics Research eXpress     Hybrid Journal   (Followers: 1, SJR: 1.241, CiteScore: 1)
Arbitration Intl.     Full-text available via subscription   (Followers: 21)
Arbitration Law Reports and Review     Hybrid Journal   (Followers: 14)
Archives of Clinical Neuropsychology     Hybrid Journal   (Followers: 30, SJR: 0.731, CiteScore: 2)
Aristotelian Society Supplementary Volume     Hybrid Journal   (Followers: 3)
Arthropod Management Tests     Hybrid Journal   (Followers: 2)
Astronomy & Geophysics     Hybrid Journal   (Followers: 44, SJR: 0.146, CiteScore: 0)
Behavioral Ecology     Hybrid Journal   (Followers: 52, SJR: 1.871, CiteScore: 3)
Bioinformatics     Hybrid Journal   (Followers: 338, SJR: 6.14, CiteScore: 8)
Biology Methods and Protocols     Hybrid Journal  
Biology of Reproduction     Full-text available via subscription   (Followers: 9, SJR: 1.446, CiteScore: 3)
Biometrika     Hybrid Journal   (Followers: 20, SJR: 3.485, CiteScore: 2)
BioScience     Hybrid Journal   (Followers: 29, SJR: 2.754, CiteScore: 4)
Bioscience Horizons : The National Undergraduate Research J.     Open Access   (Followers: 1, SJR: 0.146, CiteScore: 0)
Biostatistics     Hybrid Journal   (Followers: 17, SJR: 1.553, CiteScore: 2)
BJA : British J. of Anaesthesia     Hybrid Journal   (Followers: 186, SJR: 2.115, CiteScore: 3)
BJA Education     Hybrid Journal   (Followers: 65)
Brain     Hybrid Journal   (Followers: 68, SJR: 5.858, CiteScore: 7)
Briefings in Bioinformatics     Hybrid Journal   (Followers: 50, SJR: 2.505, CiteScore: 5)
Briefings in Functional Genomics     Hybrid Journal   (Followers: 3, SJR: 2.15, CiteScore: 3)
British J. for the Philosophy of Science     Hybrid Journal   (Followers: 36, SJR: 2.161, CiteScore: 2)
British J. of Aesthetics     Hybrid Journal   (Followers: 25, SJR: 0.508, CiteScore: 1)
British J. of Criminology     Hybrid Journal   (Followers: 605, SJR: 1.828, CiteScore: 3)
British J. of Social Work     Hybrid Journal   (Followers: 86, SJR: 1.019, CiteScore: 2)
British Medical Bulletin     Hybrid Journal   (Followers: 6, SJR: 1.355, CiteScore: 3)
British Yearbook of Intl. Law     Hybrid Journal   (Followers: 34)
Bulletin of the London Mathematical Society     Hybrid Journal   (Followers: 4, SJR: 1.376, CiteScore: 1)
Cambridge J. of Economics     Hybrid Journal   (Followers: 70, SJR: 0.764, CiteScore: 2)
Cambridge J. of Regions, Economy and Society     Hybrid Journal   (Followers: 12, SJR: 2.438, CiteScore: 4)
Cambridge Quarterly     Hybrid Journal   (Followers: 10, SJR: 0.104, CiteScore: 0)
Capital Markets Law J.     Hybrid Journal   (Followers: 2, SJR: 0.222, CiteScore: 0)
Carcinogenesis     Hybrid Journal   (Followers: 2, SJR: 2.135, CiteScore: 5)
Cardiovascular Research     Hybrid Journal   (Followers: 14, SJR: 3.002, CiteScore: 5)
Cerebral Cortex     Hybrid Journal   (Followers: 47, SJR: 3.892, CiteScore: 6)
CESifo Economic Studies     Hybrid Journal   (Followers: 22, SJR: 0.483, CiteScore: 1)
Chemical Senses     Hybrid Journal   (Followers: 1, SJR: 1.42, CiteScore: 3)
Children and Schools     Hybrid Journal   (Followers: 6, SJR: 0.246, CiteScore: 0)
Chinese J. of Comparative Law     Hybrid Journal   (Followers: 5, SJR: 0.412, CiteScore: 0)
Chinese J. of Intl. Law     Hybrid Journal   (Followers: 22, SJR: 0.329, CiteScore: 0)
Chinese J. of Intl. Politics     Hybrid Journal   (Followers: 10, SJR: 1.392, CiteScore: 2)
Christian Bioethics: Non-Ecumenical Studies in Medical Morality     Hybrid Journal   (Followers: 10, SJR: 0.183, CiteScore: 0)
Classical Receptions J.     Hybrid Journal   (Followers: 27, SJR: 0.123, CiteScore: 0)
Clean Energy     Open Access   (Followers: 1)
Clinical Infectious Diseases     Hybrid Journal   (Followers: 69, SJR: 5.051, CiteScore: 5)
Communication Theory     Hybrid Journal   (Followers: 24, SJR: 2.424, CiteScore: 3)
Communication, Culture & Critique     Hybrid Journal   (Followers: 27, SJR: 0.222, CiteScore: 1)
Community Development J.     Hybrid Journal   (Followers: 27, SJR: 0.268, CiteScore: 1)
Computer J.     Hybrid Journal   (Followers: 9, SJR: 0.319, CiteScore: 1)
Conservation Physiology     Open Access   (Followers: 3, SJR: 1.818, CiteScore: 3)
Contemporary Women's Writing     Hybrid Journal   (Followers: 9, SJR: 0.121, CiteScore: 0)
Contributions to Political Economy     Hybrid Journal   (Followers: 6, SJR: 0.906, CiteScore: 1)
Critical Values     Full-text available via subscription  
Current Developments in Nutrition     Open Access   (Followers: 2)
Current Legal Problems     Hybrid Journal   (Followers: 29)
Current Zoology     Full-text available via subscription   (Followers: 3, SJR: 1.164, CiteScore: 2)
Database : The J. of Biological Databases and Curation     Open Access   (Followers: 8, SJR: 1.791, CiteScore: 3)
Digital Scholarship in the Humanities     Hybrid Journal   (Followers: 14, SJR: 0.259, CiteScore: 1)
Diplomatic History     Hybrid Journal   (Followers: 21, SJR: 0.45, CiteScore: 1)
DNA Research     Open Access   (Followers: 5, SJR: 2.866, CiteScore: 6)
Dynamics and Statistics of the Climate System     Open Access   (Followers: 4)
Early Music     Hybrid Journal   (Followers: 17, SJR: 0.139, CiteScore: 0)
Econometrics J.     Hybrid Journal   (Followers: 32, SJR: 2.926, CiteScore: 1)
Economic J.     Hybrid Journal   (Followers: 111, SJR: 5.161, CiteScore: 3)
Economic Policy     Hybrid Journal   (Followers: 46, SJR: 3.584, CiteScore: 3)
ELT J.     Hybrid Journal   (Followers: 24, SJR: 0.942, CiteScore: 1)
English Historical Review     Hybrid Journal   (Followers: 56, SJR: 0.612, CiteScore: 1)
English: J. of the English Association     Hybrid Journal   (Followers: 17, SJR: 0.1, CiteScore: 0)
Environmental Entomology     Full-text available via subscription   (Followers: 11, SJR: 0.818, CiteScore: 2)
Environmental Epigenetics     Open Access   (Followers: 2)
Environmental History     Hybrid Journal   (Followers: 26, SJR: 0.408, CiteScore: 1)
EP-Europace     Hybrid Journal   (Followers: 3, SJR: 2.748, CiteScore: 4)
Epidemiologic Reviews     Hybrid Journal   (Followers: 9, SJR: 4.505, CiteScore: 8)
ESHRE Monographs     Hybrid Journal  
Essays in Criticism     Hybrid Journal   (Followers: 19, SJR: 0.113, CiteScore: 0)
European Heart J.     Hybrid Journal   (Followers: 66, SJR: 9.315, CiteScore: 9)
European Heart J. - Cardiovascular Imaging     Hybrid Journal   (Followers: 10, SJR: 3.625, CiteScore: 3)
European Heart J. - Cardiovascular Pharmacotherapy     Full-text available via subscription   (Followers: 2)
European Heart J. - Quality of Care and Clinical Outcomes     Hybrid Journal  
European Heart J. : Case Reports     Open Access  
European Heart J. Supplements     Hybrid Journal   (Followers: 8, SJR: 0.223, CiteScore: 0)
European J. of Cardio-Thoracic Surgery     Hybrid Journal   (Followers: 9, SJR: 1.681, CiteScore: 2)
European J. of Intl. Law     Hybrid Journal   (Followers: 199, SJR: 0.694, CiteScore: 1)
European J. of Orthodontics     Hybrid Journal   (Followers: 5, SJR: 1.279, CiteScore: 2)
European J. of Public Health     Hybrid Journal   (Followers: 20, SJR: 1.36, CiteScore: 2)
European Review of Agricultural Economics     Hybrid Journal   (Followers: 10, SJR: 1.172, CiteScore: 2)
European Review of Economic History     Hybrid Journal   (Followers: 30, SJR: 0.702, CiteScore: 1)
European Sociological Review     Hybrid Journal   (Followers: 43, SJR: 2.728, CiteScore: 3)
Evolution, Medicine, and Public Health     Open Access   (Followers: 12)
Family Practice     Hybrid Journal   (Followers: 16, SJR: 1.018, CiteScore: 2)
Fems Microbiology Ecology     Hybrid Journal   (Followers: 16, SJR: 1.492, CiteScore: 4)
Fems Microbiology Letters     Hybrid Journal   (Followers: 28, SJR: 0.79, CiteScore: 2)
Fems Microbiology Reviews     Hybrid Journal   (Followers: 32, SJR: 7.063, CiteScore: 13)
Fems Yeast Research     Hybrid Journal   (Followers: 13, SJR: 1.308, CiteScore: 3)
Food Quality and Safety     Open Access   (Followers: 1)
Foreign Policy Analysis     Hybrid Journal   (Followers: 24, SJR: 1.425, CiteScore: 1)
Forest Science     Hybrid Journal   (Followers: 8, SJR: 0.89, CiteScore: 2)
Forestry: An Intl. J. of Forest Research     Hybrid Journal   (Followers: 16, SJR: 1.133, CiteScore: 3)
Forum for Modern Language Studies     Hybrid Journal   (Followers: 6, SJR: 0.104, CiteScore: 0)
French History     Hybrid Journal   (Followers: 33, SJR: 0.118, CiteScore: 0)
French Studies     Hybrid Journal   (Followers: 21, SJR: 0.148, CiteScore: 0)
French Studies Bulletin     Hybrid Journal   (Followers: 10, SJR: 0.152, CiteScore: 0)
Gastroenterology Report     Open Access   (Followers: 2)
Genome Biology and Evolution     Open Access   (Followers: 16, SJR: 2.578, CiteScore: 4)
Geophysical J. Intl.     Hybrid Journal   (Followers: 39, SJR: 1.506, CiteScore: 3)
German History     Hybrid Journal   (Followers: 23, SJR: 0.161, CiteScore: 0)
GigaScience     Open Access   (Followers: 5, SJR: 5.022, CiteScore: 7)
Global Summitry     Hybrid Journal   (Followers: 1)
Glycobiology     Hybrid Journal   (Followers: 13, SJR: 1.493, CiteScore: 3)
Health and Social Work     Hybrid Journal   (Followers: 57, SJR: 0.388, CiteScore: 1)
Health Education Research     Hybrid Journal   (Followers: 16, SJR: 0.854, CiteScore: 2)
Health Policy and Planning     Hybrid Journal   (Followers: 24, SJR: 1.512, CiteScore: 2)
Health Promotion Intl.     Hybrid Journal   (Followers: 22, SJR: 0.812, CiteScore: 2)
History Workshop J.     Hybrid Journal   (Followers: 33, SJR: 1.278, CiteScore: 1)
Holocaust and Genocide Studies     Hybrid Journal   (Followers: 28, SJR: 0.105, CiteScore: 0)
Human Communication Research     Hybrid Journal   (Followers: 15, SJR: 2.146, CiteScore: 3)
Human Molecular Genetics     Hybrid Journal   (Followers: 9, SJR: 3.555, CiteScore: 5)
Human Reproduction     Hybrid Journal   (Followers: 72, SJR: 2.643, CiteScore: 5)
Human Reproduction Open     Open Access   (Followers: 1)
Human Reproduction Update     Hybrid Journal   (Followers: 20, SJR: 5.317, CiteScore: 10)
Human Rights Law Review     Hybrid Journal   (Followers: 62, SJR: 0.756, CiteScore: 1)
ICES J. of Marine Science: J. du Conseil     Hybrid Journal   (Followers: 58, SJR: 1.591, CiteScore: 3)
ICSID Review : Foreign Investment Law J.     Hybrid Journal   (Followers: 10)
ILAR J.     Hybrid Journal   (Followers: 2, SJR: 1.732, CiteScore: 4)
IMA J. of Applied Mathematics     Hybrid Journal   (SJR: 0.679, CiteScore: 1)
IMA J. of Management Mathematics     Hybrid Journal   (SJR: 0.538, CiteScore: 1)
IMA J. of Mathematical Control and Information     Hybrid Journal   (Followers: 2, SJR: 0.496, CiteScore: 1)
IMA J. of Numerical Analysis - advance access     Hybrid Journal   (SJR: 1.987, CiteScore: 2)
Industrial and Corporate Change     Hybrid Journal   (Followers: 9, SJR: 1.792, CiteScore: 2)
Industrial Law J.     Hybrid Journal   (Followers: 39, SJR: 0.249, CiteScore: 1)
Inflammatory Bowel Diseases     Hybrid Journal   (Followers: 47, SJR: 2.511, CiteScore: 4)
Information and Inference     Free  
Innovation in Aging     Open Access  
Integrative and Comparative Biology     Hybrid Journal   (Followers: 9, SJR: 1.319, CiteScore: 2)
Integrative Biology     Full-text available via subscription   (Followers: 6, SJR: 1.36, CiteScore: 3)
Integrative Organismal Biology     Open Access  
Interacting with Computers     Hybrid Journal   (Followers: 11, SJR: 0.292, CiteScore: 1)
Interactive CardioVascular and Thoracic Surgery     Hybrid Journal   (Followers: 7, SJR: 0.762, CiteScore: 1)
Intl. Affairs     Hybrid Journal   (Followers: 66, SJR: 1.505, CiteScore: 3)
Intl. Data Privacy Law     Hybrid Journal   (Followers: 26)
Intl. Health     Hybrid Journal   (Followers: 6, SJR: 0.851, CiteScore: 2)
Intl. Immunology     Hybrid Journal   (Followers: 3, SJR: 2.167, CiteScore: 4)
Intl. J. for Quality in Health Care     Hybrid Journal   (Followers: 36, SJR: 1.348, CiteScore: 2)
Intl. J. of Constitutional Law     Hybrid Journal   (Followers: 64, SJR: 0.601, CiteScore: 1)
Intl. J. of Epidemiology     Hybrid Journal   (Followers: 247, SJR: 3.969, CiteScore: 5)
Intl. J. of Law and Information Technology     Hybrid Journal   (Followers: 5, SJR: 0.202, CiteScore: 1)
Intl. J. of Law, Policy and the Family     Hybrid Journal   (Followers: 28, SJR: 0.223, CiteScore: 1)
Intl. J. of Lexicography     Hybrid Journal   (Followers: 10, SJR: 0.285, CiteScore: 1)
Intl. J. of Low-Carbon Technologies     Open Access   (Followers: 1, SJR: 0.403, CiteScore: 1)
Intl. J. of Neuropsychopharmacology     Open Access   (Followers: 3, SJR: 1.808, CiteScore: 4)
Intl. J. of Public Opinion Research     Hybrid Journal   (Followers: 11, SJR: 1.545, CiteScore: 1)
Intl. J. of Refugee Law     Hybrid Journal   (Followers: 38, SJR: 0.389, CiteScore: 1)
Intl. J. of Transitional Justice     Hybrid Journal   (Followers: 11, SJR: 0.724, CiteScore: 2)
Intl. Mathematics Research Notices     Hybrid Journal   (Followers: 1, SJR: 2.168, CiteScore: 1)
Intl. Political Sociology     Hybrid Journal   (Followers: 40, SJR: 1.465, CiteScore: 3)
Intl. Relations of the Asia-Pacific     Hybrid Journal   (Followers: 23, SJR: 0.401, CiteScore: 1)
Intl. Studies Perspectives     Hybrid Journal   (Followers: 9, SJR: 0.983, CiteScore: 1)
Intl. Studies Quarterly     Hybrid Journal   (Followers: 49, SJR: 2.581, CiteScore: 2)
Intl. Studies Review     Hybrid Journal   (Followers: 25, SJR: 1.201, CiteScore: 1)
ISLE: Interdisciplinary Studies in Literature and Environment     Hybrid Journal   (Followers: 2, SJR: 0.15, CiteScore: 0)
ITNOW     Hybrid Journal   (Followers: 1, SJR: 0.103, CiteScore: 0)
J. of African Economies     Hybrid Journal   (Followers: 17, SJR: 0.533, CiteScore: 1)
J. of American History     Hybrid Journal   (Followers: 46, SJR: 0.297, CiteScore: 1)
J. of Analytical Toxicology     Hybrid Journal   (Followers: 14, SJR: 1.065, CiteScore: 2)
J. of Antimicrobial Chemotherapy     Hybrid Journal   (Followers: 15, SJR: 2.419, CiteScore: 4)
J. of Antitrust Enforcement     Hybrid Journal   (Followers: 1)
J. of Applied Poultry Research     Hybrid Journal   (Followers: 5, SJR: 0.585, CiteScore: 1)
J. of Biochemistry     Hybrid Journal   (Followers: 41, SJR: 1.226, CiteScore: 2)
J. of Breast Imaging     Full-text available via subscription  
J. of Burn Care & Research     Hybrid Journal   (Followers: 10, SJR: 0.768, CiteScore: 2)

        1 2 3 | Last   [Sort by number of followers]   [Restore default list]

Similar Journals
Journal Cover
Annals of Oncology
Journal Prestige (SJR): 5.599
Citation Impact (citeScore): 9
Number of Followers: 56  
 
  Hybrid Journal Hybrid journal (It can contain Open Access articles)
ISSN (Print) 0923-7534 - ISSN (Online) 1569-8041
Published by Oxford University Press Homepage  [406 journals]
  • LBA2Patient-reported outcomes (PROs) with durvalumab by PD-L1 expression
           in unresectable, stage III NSCLC (PACIFIC)
    • Authors: Garassino M; Paz-Ares L, Hui R, et al.
      Abstract: Background: In the phase 3 PACIFIC study of unresectable, Stage III NSCLC pts without progression after platinum-based concurrent chemoradiotherapy (cCRT), the primary endpoints PFS and OS were significantly improved with durvalumab versus placebo with similar safety and no detrimental effect on PROs. We retrospectively investigated the impact of tumour PD-L1 expression on PROs to better understand the benefit/risk profile of durvalumab across all PD-L1 subgroups.
      PubDate: Sat, 13 Apr 2019 00:00:00 GMT
      DOI: 10.1093/annonc/mdz094.001
      Issue No: Vol. 30, No. Supplement_2 (2019)
       
  • 185TiPRATIONALE 001: Tislelizumab (BGB-A317) + concurrent
           chemoradiotherapy (cCRT) followed by tislelizumab monotherapy in patients
           (pts) with newly diagnosed locally advanced, unresectable, stage III
           non-small cell lung cancer (NSCLC)
    • Authors: Paz-Ares L; Senan S, Planchard D, et al.
      Abstract: Background: In pts with locally advanced, unresectable, stage III NSCLC, cCRT is associated with better survival than radiotherapy (RT) alone, but 5-y survival remains poor. Immunotherapies targeting PD-1/PD-L1 may be synergistic with cCRT, improving outcomes. Tislelizumab, an anti–PD-1 antibody, showed clinical activity/tolerability in solid tumors, including NSCLC. RATIONALE 001 is a phase III, randomized, double-blind, placebo-controlled trial evaluating the efficacy and safety of first-line tislelizumab + cCRT in pts with locally advanced, unresectable, stage III NSCLC.
      PubDate: Sat, 13 Apr 2019 00:00:00 GMT
      DOI: 10.1093/annonc/mdz063.083
      Issue No: Vol. 30, No. Supplement_2 (2019)
       
  • Translational Research Index
    • Abstract: A3 receptor: 13P
      PubDate: Sat, 13 Apr 2019 00:00:00 GMT
      DOI: 10.1093/annonc/mdz093
      Issue No: Vol. 30, No. Supplement_2 (2019)
       
  • 2ODifferentially regulated high-throughput CT imaging features correlate
           to distinct tumor immune contextures portraying a radiomic signature with
           prognostic impact on surgically resected NSCLC
    • Authors: Mazzaschi G; Quaini F, Milanese G, et al.
      Abstract: Background: The ground-breaking advent of immunotherapy in the oncologic arena still leaves uncovered the identification of valid prognostic and predictive biomarkers. To this aim, we advanced the hypothesis that intersecting the tumor immune microenvironment (TIME) with high-throughput extracted radiomic features may identify NSCLC patients with distinct clinical outcome.
      PubDate: Sat, 13 Apr 2019 00:00:00 GMT
      DOI: 10.1093/annonc/mdz072.001
      Issue No: Vol. 30, No. Supplement_2 (2019)
       
  • 184TiPFIND: A phase II study to evaluate the efficacy of erdafitinib in
           FGFR-altered squamous NSCLC
    • Authors: Nogova L; Malchers F, Hillmer A, et al.
      Abstract: Background: Genomic FGFR alterations and their oncogenic driver potential are frequently observed in various cancers. Initial clinical trials with selective FGFR inhibitors showed moderate responses in FGFR amplified squamous NSCLC (sqNSCLC) patients. However, in FGFR mutated or translocated tumor types a response rate of above 30% was observed. Preclinical cell line and patient-derived sqNSCLC xenograft models with FGFR mutations or translocations indicate strong oncogenic activity and potential sensitivity to FGFR inhibitors. Approximately 3% of all sqNSCLC patients harbor somatic alterations within FGFR genes. However, only some of these mutations are shown to be oncogenic drivers in vitro and in vivo experiments or first in man trials.
      PubDate: Sat, 13 Apr 2019 00:00:00 GMT
      DOI: 10.1093/annonc/mdz063.082
      Issue No: Vol. 30, No. Supplement_2 (2019)
       
  • Drug Index
    • Abstract: A3 receptor antagonist: 13P
      PubDate: Sat, 13 Apr 2019 00:00:00 GMT
      DOI: 10.1093/annonc/mdz092
      Issue No: Vol. 30, No. Supplement_2 (2019)
       
  • 183TiPA phase II study of [fam-] trastuzumab deruxtecan (DS-8201a) in
           HER2-overexpressing or -mutated advanced non-small cell lung cancer
    • Authors: Planchard D; Li B, Murakami H, et al.
      Abstract: Background: Approximately 30% of non-small-cell lung cancers (NSCLC) are human epidermal growth factor receptor 2 (HER2)-overexpressing (immunohistochemistry [IHC] 2+ or 3+) and approximately 2% have HER2-activating mutations. However, no HER2-targeted therapies are approved for the treatment of NSCLC. [Fam-] trastuzumab deruxtecan (DS-8201a) is a novel HER2-targeted antibody-drug conjugate with a humanized HER2 antibody, a topoisomerase I inhibitor payload, cleavable peptide-based linker, and a high drug-to-antibody ratio of 7 to 8. In an ongoing phase 1 trial, [fam-] trastuzumab deruxtecan (6.4 mg/kg) had a confirmed objective response rate (ORR) of 58.8% (10/17) in HER2-expressing or -mutated NSCLC and 72.7% (8/11) in HER2-mutated NSCLC, with a manageable safety profile (Tsurutani et al, WCLC 2018).
      PubDate: Sat, 13 Apr 2019 00:00:00 GMT
      DOI: 10.1093/annonc/mdz063.081
      Issue No: Vol. 30, No. Supplement_2 (2019)
       
  • 60PNomogram for patients with stage I small cell lung cancer: A competing
           risk analysis
    • Authors: Liu J; Zhou H, Zhang Y, et al.
      Abstract: Background: Small-cell lung cancer (SCLC), accounting for about 15% of all lung cancers, is a subtype of lung cancer with poor prognosis. It has a 5-year survival rate of 7% and kills an estimated 250,000 people worldwide annually. Although many studies have estimated the prognosis of SCLC, most of them were conducted without considering competing risks. This study aimed to evaluate the probability of cause-specific death for patients with stage I small cell lung cancer (SCLC) with a competing risk analysis.
      PubDate: Sat, 13 Apr 2019 00:00:00 GMT
      DOI: 10.1093/annonc/mdz071
      Issue No: Vol. 30, No. Supplement_2 (2019)
       
  • 21OEPAC-Lung: Pooled analysis of circulating tumor cells in advanced
           non-small cell lung cancer
    • Authors: Lindsay C; Blackhall F, Carmel A, et al.
      Abstract: Background: We assessed the clinical validity of circulating tumor cell (CTC) quantification for prognostication of patients with advanced non-small cell lung cancer (NSCLC) by undertaking a European pooled analysis of individual patient data. This is the largest study of its kind and the first to examine between-centre heterogeneity of CTC identification in NSCLC.
      PubDate: Sat, 13 Apr 2019 00:00:00 GMT
      DOI: 10.1093/annonc/mdz073
      Issue No: Vol. 30, No. Supplement_2 (2019)
       
  • LBA1_PRNivolumab (nivo) plus ipilimumab (ipi), nivo, or placebo (pbo) as
           maintenance therapy in patients (pts) with extensive disease small cell
           lung cancer (ED-SCLC) after first-line (1L) platinum-based chemotherapy
           (chemo): Results from the double-blind, randomized phase III CheckMate 451
           study
    • Authors: Owonikoko T; Kim H, Govindan R, et al.
      Abstract: Background: In pts with ED-SCLC, response rates to 1L platinum-based chemo are high but lack durability. Treatments (txs) that prolong response duration and improve survival are needed. CheckMate 451 (NCT02538666) is a global, double-blind, phase 3 study of nivo+ipi or nivo vs pbo as maintenance therapy in pts with ED-SCLC who did not progress on 1L platinum-based chemo.
      PubDate: Sat, 13 Apr 2019 00:00:00 GMT
      DOI: 10.1093/annonc/mdz094
      Issue No: Vol. 30, No. Supplement_2 (2019)
       
  • 202PInformation for lung cancer patients and their caregivers: A
           systematic analysis of the online landscape
    • Authors: Naish P; Purdy E.
      Abstract: Background: A lung cancer patient may turn to the internet for information on their disease, or on terms that their doctor has used. Anecdotal evidence suggests that such information may be outdated or incomplete. This research analyses the information available on lung cancer, aiming to support the identification of areas for improvement to ensure patients can be well-informed.
      PubDate: Sat, 13 Apr 2019 00:00:00 GMT
      DOI: 10.1093/annonc/mdz065.002
      Issue No: Vol. 30, No. Supplement_2 (2019)
       
  • 182TiPA phase II trial of tepotinib in patients with non-small cell lung
           cancer (NSCLC) harboring MET alterations: The VISION study
    • Authors: Paik P; Cortot A, Felip E, et al.
      Abstract: Background: Dysregulation of the MET pathway is common in human carcinomas and leads to dependency on MET signalling, representing a potential therapeutic target in NSCLC. MET alterations including MET-exon 14 skipping mutations (METex14) and MET amplification (METamp) are known oncogenic drivers, and occur in 3–4% and 0.4–1.5% of NSCLCs, respectively. Tepotinib, a potent selective, small molecule MET inhibitor, has shown promise in preclinical and phase 1 trials.
      PubDate: Sat, 13 Apr 2019 00:00:00 GMT
      DOI: 10.1093/annonc/mdz063.080
      Issue No: Vol. 30, No. Supplement_2 (2019)
       
  • 39PHigh dose apatinib in the reversal of immunosuppressive tumor
           microenvironment for irradiation therapy in lung carcinoma
    • Authors: Liang L; Hu C, Wen Y, et al.
      Abstract: Background: This study aimed to investigate the potential systemic anti-tumor effects of stereotactic ablative radiotherapy (SABR) and apatinib (a novel vascular endothelial growth factor receptor 2 tyrosine kinase inhibitor) via reversing the immunosuppressive tumor microenvironment for lung carcinoma.
      PubDate: Sat, 13 Apr 2019 00:00:00 GMT
      DOI: 10.1093/annonc/mdz073.018
      Issue No: Vol. 30, No. Supplement_2 (2019)
       
  • 41PDiagnostic accuracy of droplet digital PCR (ddPCR) and amplification
           refractory mutation system PCR (ARMS-PCR) for detecting EGFR mutation in
           cell-free DNA of advanced lung cancer: A meta-analysis
    • Authors: Li C; He Q, Liang H, et al.
      Abstract: Background: Epidermal growth factor receptor (EGFR) mutation testing in plasma cell-free DNA (cfDNA) from advanced lung cancer patients is an emerging clinical tool. This non-invasive approach may offer genotyping information but prevent patients from the shortcomings of invasive and repeated biopsies. This meta-analysis was designed to determine the diagnostic accuracy of two common PCR systems, ddPCR and ARMS-PCR, for detecting EGFR mutation in cfDNA.
      PubDate: Sat, 13 Apr 2019 00:00:00 GMT
      DOI: 10.1093/annonc/mdz073.020
      Issue No: Vol. 30, No. Supplement_2 (2019)
       
  • 67TiPADRIATIC: A phase III trial of durvalumab ± tremelimumab after
           concurrent chemoradiation for patients with limited stage small cell lung
           cancer
    • Authors: Senan S; Shire N, Mak G, et al.
      Abstract: Background: Limited stage small-cell lung cancer (LS-SCLC), which represents ∼30% of newly diagnosed SCLC, remains an area of high unmet medical need. Standard of care, which has not changed for several decades, consists of curative intent platinum-based chemotherapy concurrent with radiotherapy (cCRT) followed by prophylactic brain irradiation (PCI) and observation. Despite good response to cCRT, outcomes remain poor, with median progression-free survival (PFS) ∼15 months and overall survival (OS) ∼25 months. Durvalumab (D) is a selective, high-affinity, human IgG1 monoclonal antibody (mAb) that blocks programmed cell death ligand-1 binding to programmed cell death-1 and CD80. Tremelimumab (T) is a selective human IgG2 mAb against CTLA-4. D demonstrated a PFS and OS advantage over placebo in locally advanced NSCLC following cCRT. D and D + T demonstrated a tolerable safety profile and antitumour activity in pretreated extensive stage SCLC. The ADRIATIC trial (NCT03703297) will assess if treatment with D ± T is beneficial vs placebo in patients (pts) with LS-SCLC who have not progressed following cCRT.
      PubDate: Sat, 13 Apr 2019 00:00:00 GMT
      DOI: 10.1093/annonc/mdz071.007
      Issue No: Vol. 30, No. Supplement_2 (2019)
       
  • LBA4Effect of post-study immunotherapy (IO) on overall survival (OS)
           outcome in patients with metastatic (m) NSCLC treated with first-line
           durvalumab (D) vs chemotherapy (CT) in the phase III MYSTIC study
    • Authors: Reinmuth N; Cho B, Lee K, et al.
      Abstract: Background: In MYSTIC (NCT02453282), an open-label, Phase 3 study of first-line D (anti-PD-L1) ± tremelimumab vs platinum-based CT in mNSCLC, while not statistically significant, a clinically meaningful improvement in OS was seen with D vs CT in pts with tumour cell PD-L1 expression ≥25% (PD-L1 TC ≥25%; HR 0.76 [97.54% CI 0.56–1.02], p=0.036). Here we describe subsequent treatment patterns and explore the effect of subsequent IO on the OS outcome with D vs CT.
      PubDate: Sat, 13 Apr 2019 00:00:00 GMT
      DOI: 10.1093/annonc/mdz094.003
      Issue No: Vol. 30, No. Supplement_2 (2019)
       
  • 201PPsychosocial and financial impact on family of lung cancer patients: A
           cancer research center experience
    • Authors: Godara S; Beniwal S.
      Abstract: Background: Caregivers play a critical role and most affected peoples in the oncology setting and having an understanding of this may assist health care professionals in supporting them with these tasks, and targeting services towards those most in need. Cancer is one of the most common health conditions to receive informal caregiving, with the majority of caregivers reporting taking on this role because of family responsibility and there being little choice or no one else to provide the care.
      PubDate: Sat, 13 Apr 2019 00:00:00 GMT
      DOI: 10.1093/annonc/mdz065.001
      Issue No: Vol. 30, No. Supplement_2 (2019)
       
  • 181TiP Phase II study of crizotinib in Japanese patients with advanced
           non-small cell lung cancer harboring a MET gene alteration: Co-MET study
    • Authors: Shimokawa M; Nosaki K, Seto T, et al.
      Abstract: Background: The majority of non-small cell lung cancer (NSCLC) patients are diagnosed as metastatic disease for which no curative treatment is available. Phase III randomized trials of tyrosine kinase inhibitor (TKI) therapy for EGFR-mutant and anaplastic lymphoma receptor tyrosine kinase (ALK)-rearranged lung cancers have documented improvements in response and progression-free survival (PFS), and TKIs are approved for the treatment of patients with oncogene-driver mutations. c-Met is the tyrosine kinase receptor for hepatocyte growth factor, and MET gene alterations including MET exon14 skipping mutation-positive or MET high gene copy number are known to be an oncogene via activation of c-MET signaling pathway. Crizotinib is a selective ATP-competitive small-molecule inhibitor of c-Met, ALK and ROS1 tyrosine kinases. Durable responses to crizotinib were reported in patients with advanced NSCLC harboring MET exon 14 skipping mutation or high MET gene copy number. Therefore, we considered to assess the efficacy and safety of crizotinib in patients with advanced NSCLC harboring a MET gene alteration.
      PubDate: Sat, 13 Apr 2019 00:00:00 GMT
      DOI: 10.1093/annonc/mdz063.079
      Issue No: Vol. 30, No. Supplement_2 (2019)
       
  • 38PHedgehog pathway activation might mediate pemetrexed resistance in
           NSCLC cells
    • Authors: Liu Y; Kiefl R, Huber R, et al.
      Abstract: Background: Lung cancer is the leading cause of death among all other malignancies. Despite the wide use and the high efficacy of immunotherapy, most patients with advanced or metastatic disease need chemotherapeutic treatment. Primary and acquired resistance to chemotherapeutic agents are the main cause of reduced overall survival. The Hedgehog (HH) pathway has been shown to be crucial in cell development and survival. Activated in several types of cancer it might be a potent bypass mechanism mediating chemo resistance. Thus, this study aims at investigating the role of HH signalling in chemo resistant NSCLC cells.
      PubDate: Sat, 13 Apr 2019 00:00:00 GMT
      DOI: 10.1093/annonc/mdz073.017
      Issue No: Vol. 30, No. Supplement_2 (2019)
       
  • 40PThe metabolic phenotypes of non-small cell lung cancer cells in
           association with clinical treatment strategies
    • Authors: Kuo T; Hsiao T, Yang P.
      Abstract: Background: In 2011, metabolic reprogramming was defined as one of the cancer hallmarks, and several drugs targeting cancer metabolism have been developed as anti-cancer drugs. To improve medication efficiency of these anti-metabolic drugs, we tried to sub-classify non-small cell lung cancer (NSCLC) cells by their glycolytic dependency and treat them by targeting different metabolism-related proteins.
      PubDate: Sat, 13 Apr 2019 00:00:00 GMT
      DOI: 10.1093/annonc/mdz073.019
      Issue No: Vol. 30, No. Supplement_2 (2019)
       
  • 66PTreatment (tx) characteristics and clinical outcomes in patients (pts)
           with extensive-stage small cell lung cancer (ES-SCLC) treated with
           carboplatin (carbo) or cisplatin (cis) in combination with etoposide
           (etop) in US clinical practice
    • Authors: Sebastian M; Barlesi F, Califano R, et al.
      Abstract: Background: For pts with ES-SCLC, guidelines recommend carbo or cis + etop as first-line (1L) tx. However, real-world data (RWD) on tx patterns and outcomes are limited. Here, we describe pt characteristics, tx duration and clinical outcomes associated with these 2 regimens.
      PubDate: Sat, 13 Apr 2019 00:00:00 GMT
      DOI: 10.1093/annonc/mdz071.006
      Issue No: Vol. 30, No. Supplement_2 (2019)
       
  • LBA3Efficacy and safety of first-line durvalumab (D) ± tremelimumab (T)
           vs platinum-based chemotherapy (CT) based on clinical characteristics in
           patients with metastatic (m) NSCLC: Results from MYSTIC
    • Authors: Cho B; Reinmuth N, Lee K, et al.
      Abstract: Background: In MYSTIC (NCT02453282), an open-label, Phase 3 trial of first-line D (anti-PD-L1) ± T (anti-CTLA-4) vs CT in mNSCLC, while not statistically significant, a clinically meaningful improvement in overall survival (OS) was seen with D vs CT in pts with tumour cell PD-L1 expression ≥25% (TC ≥25% [primary analysis population]; D vs CT, HR 0.76 [97.54% CI 0.56–1.02], p=0.036; D+T vs CT, HR 0.85 [98.77% CI 0.61–1.17], p=0.202). Here we report OS in clinically relevant pt subgroups and safety results from MYSTIC.
      PubDate: Sat, 13 Apr 2019 00:00:00 GMT
      DOI: 10.1093/annonc/mdz094.002
      Issue No: Vol. 30, No. Supplement_2 (2019)
       
  • 24PA new bioinformatic pipeline allows the design of small, targeted gene
           panels for efficient TMB estimation
    • Authors: Manca P; Mallona I, Santini D, et al.
      Abstract: Background: The tumor mutation burden (TMB) is emerging as a prognostic and predictive marker for the response to immune checkpoint blockade (ICB) drugs. We aimed to develop a new method for the definition of gene panels that can precisely estimate the TMB with a considerably lower amount of genome.
      PubDate: Sat, 13 Apr 2019 00:00:00 GMT
      DOI: 10.1093/annonc/mdz073.003
      Issue No: Vol. 30, No. Supplement_2 (2019)
       
  • 143PRole of radiotherapy in management of brain metastases in anaplastic
           lymphoma kinase (ALK)-rearranged non-small cell lung cancer (NSCLC): A
           single-center retrospective study
    • Authors: Zhao Y; Zhang B, Zhang Y, et al.
      Abstract: Background: Targeted therapies provide benefits in ALK-rearranged patients with brain metastases (BM). However, role of radiotherapy in these patients hasn’t been established. This study sought to determine if upfront radiotherapy in combination with targeted therapies can impact patient outcomes.
      PubDate: Sat, 13 Apr 2019 00:00:00 GMT
      DOI: 10.1093/annonc/mdz063.041
      Issue No: Vol. 30, No. Supplement_2 (2019)
       
  • 68OElectromagnetic navigation bronchoscopy in the European cohort of the
           prospective, multicenter NAVIGATE study
    • Authors: Lau K; Flandes J, Christensen M, et al.
      Abstract: Background: Electromagnetic navigation bronchoscopy (ENB) is an image-guided approach to access peripheral pulmonary lesions. ENB has been evaluated in a prospective global study (NAVIGATE, NCT02410837, Khandhar, BMC Pulm Med 2017;17:59). Practice patterns and safety specifically in the full European cohort have not yet been presented. The objective of this study is to evaluate ENB safety and usage in the NAVIGATE European sites.
      PubDate: Sat, 13 Apr 2019 00:00:00 GMT
      DOI: 10.1093/annonc/mdz064
      Issue No: Vol. 30, No. Supplement_2 (2019)
       
  • 180TiPAn open-label, randomized, phase I/II trial of IO102 and
           pembrolizumab, or IO102, pembrolizumab and chemotherapy, as first-line
           treatment for patients with metastatic non-small cell lung cancer
    • Authors: Spicer J; Provencio M, Garrido Lopez P, et al.
      Abstract: Background: Immunotherapy has significantly changed the treatment landscape of non-small cell lung cancer (NSCLC) with no driver mutations. However, despite the addition of anti-PD-1/PD-L1 therapies to the clinical armamentarium only a subset of patients derives durable benefit. IO102 is a novel, second generation, HLA-A unrestricted immune modulating T-win® vaccine targeting IDO. IO102 has a dual mode of action; remodulation of the tumour micro-environment through elimination of immune suppressive cells and induction of CD8 T-cell mediated killing of IDO-expressing tumor cells. Our first-generation IDO vaccine (IO101) has shown promising antitumor activity and a favorable safety in heavily pretreated NSCLC patients (Iversen, CCR 2013).
      PubDate: Sat, 13 Apr 2019 00:00:00 GMT
      DOI: 10.1093/annonc/mdz063.078
      Issue No: Vol. 30, No. Supplement_2 (2019)
       
  • 196OSTELLAR: Final updated results of a phase II trial of TTFields with
           chemotherapy for unresectable malignant pleural mesothelioma
    • Authors: Ceresoli G; Aerts J, Dziadziuszko R, et al.
      Abstract: Background: Tumor Treating Fields (TTFields), an anti-mitotic, regional treatment approved for glioblastoma utilizes low intensity, alternating electric fields delivered non-invasively to the tumor using a portable medical device. In-vitro, human mesothelioma cells were highly susceptible to TTFields.
      PubDate: Sat, 13 Apr 2019 00:00:00 GMT
      DOI: 10.1093/annonc/mdz069
      Issue No: Vol. 30, No. Supplement_2 (2019)
       
  • 91PPrognosis of EGFR-mutant advanced lung adenocarcinoma patients with
           different intrathoracic metastatic patterns
    • Authors: Hu F; Zhang B, Li C, et al.
      Abstract: Background: Lung cancer diagnosed solely with intrathoracic metastases are classified as M1a, but intrathoracic metastases can be further divided into different patterns. The objective of our study was to analyze the survival difference between different metastatic patterns of intrathoracic metastases in lung adenocarcinoma patients with epidermal growth factor receptor (EGFR) mutations.
      PubDate: Sat, 13 Apr 2019 00:00:00 GMT
      DOI: 10.1093/annonc/mdz067.007
      Issue No: Vol. 30, No. Supplement_2 (2019)
       
  • 65PExperience of prophylactic cranial irradiation in extensive stage small
           cell lung cancer at a regional cancer center in India
    • Authors: Jat R; Rai R, Jakhar S, et al.
      Abstract: Background: We conducted this randomized trial at our center to assess benefits of prophylactic cranial irradiation (PCI) in cases of extensive stage small cell lung cancer (eSCLC), who showed complete or partial response to 4 cycles of cisplatin and etoposide chemotherapy-based regime.
      PubDate: Sat, 13 Apr 2019 00:00:00 GMT
      DOI: 10.1093/annonc/mdz071.005
      Issue No: Vol. 30, No. Supplement_2 (2019)
       
  • 164PPD-L1 expression affect the efficacy of pemetrexed maintenance therapy
           in real-world patients with advanced non-squamous NSCLC
    • Authors: Qin Y; Jiang L, Li Y, et al.
      Abstract: Background: It has been demonstrated that pemetrexed maintenance therapy is an effective and well tolerated option for patients with advanced non-squamous non-small cell lung cancer (NSCLC). This study aimed to investigate the impacts of clinical features, gene status and PD-L1 expression on the efficacy of pemetrexed maintenance therapy in real-world.
      PubDate: Sat, 13 Apr 2019 00:00:00 GMT
      DOI: 10.1093/annonc/mdz063.062
      Issue No: Vol. 30, No. Supplement_2 (2019)
       
  • 37PGenetic variation of lymphotoxin beta receptor (LTβR) rs10849448 (A/G)
           
    • Authors: Dimitrakopoulos F; Antonacopoulou A, Kottorou A, et al.
      Abstract: Background: During the last years there is an expansion of our knowledge in lung cancer immunology. In addition, there is a growing number of studies on the role of lymphotoxin beta receptor (LTβR), a member of the tumor necrosis factor (TNF) family, which plays an important role in lymphoid system formation and homeostasis as well as in immune system regulation mainly through NF-κB signaling. The aim of the current study was to investigate the clinical relevance of LTβR single nucleotide polymorphism (SNP) rs10849448 (A/G) with the susceptibility to NSCLC, the clinicopathological parameters, the relapse and the survival rates of NSCLC patients, as well as with the protein expression of LTβR.
      PubDate: Sat, 13 Apr 2019 00:00:00 GMT
      DOI: 10.1093/annonc/mdz073.016
      Issue No: Vol. 30, No. Supplement_2 (2019)
       
  • 23PImmunosenescence (iSenescence) correlates with progression (PD) to
           PD-(L)1 inhibitors (IO) and not to platinum-chemotherapy (PCT) in advanced
           non-small cell lung cancer (aNSCLC) patients (pts)
    • Authors: Ferrara R; Naigeon M, Auclin E, et al.
      Abstract: Background: iSenescence is a remodeling of immune functions with a multifactorial etiology (i.e. aging, chronic inflammation, cancer). Although the absence of CD28 and the expression of CD57 and KLRG1 on circulating T-lymphocytes are hallmarks of iSenescence, the characterization of such phenotype in aNSCLC pts and the correlation with clinical characteristics and benefit from IO or PCT are currently unknown.
      PubDate: Sat, 13 Apr 2019 00:00:00 GMT
      DOI: 10.1093/annonc/mdz073.002
      Issue No: Vol. 30, No. Supplement_2 (2019)
       
  • 122POsimertinib as first-line (1L) treatment for epidermal growth factor
           receptor (EGFR) mutation-positive advanced non-small cell lung cancer
           (NSCLC): Final efficacy and safety results from two phase I expansion
           cohorts
    • Authors: Yang J; Ramalingam S, Lee C, et al.
      Abstract: Background: Osimertinib is a 3rd-generation, CNS-active EGFR-tyrosine kinase inhibitor (TKI) that potently and selectively inhibits both EGFR-TKI sensitising (EGFRm) and EGFR T790M resistance mutations. Earlier results from the Ph I AURA (NCT01802632) and Ph III FLAURA (NCT02296125) studies have established 1L osimertinib efficacy. We report final efficacy and safety data from two Ph I expansion cohorts who received 1L osimertinib 80 or 160 mg for advanced EGFRm NSCLC in AURA.
      PubDate: Sat, 13 Apr 2019 00:00:00 GMT
      DOI: 10.1093/annonc/mdz063.020
      Issue No: Vol. 30, No. Supplement_2 (2019)
       
  • 142PClinical management of advanced lung adenocarcinoma with ALK
           rearrangement: Real-world treatment outcomes and long-term survival
    • Authors: Zhang B; Wang S, Xu J, et al.
      Abstract: Background: Anaplastic lymphoma kinase-tyrosine kinase inhibitors (ALK-TKIs) have been demonstrated to be effective in ALK-rearranged, advanced lung adenocarcinoma patients. However, data from a real-world setting is very limited. The aim of the study was to: a) determine long-term survival in these patients and investigate factors associated with their prognosis; and b) analyze the clinical outcomes of patients who were sequentially treated with next-generation ALK-TKIs.
      PubDate: Sat, 13 Apr 2019 00:00:00 GMT
      DOI: 10.1093/annonc/mdz063.040
      Issue No: Vol. 30, No. Supplement_2 (2019)
       
  • 199PSafety meta-analysis of clinical trials delivering TTFields to the
           upper torso
    • Authors: Ceresoli G; Pless M.
      Abstract: Background: Tumor Treating Fields (TTFields), a non-invasive, loco-regional, antimitotic treatment approved for glioblastoma (GBM), are delivered via transducer arrays to tumor region. Localized dermatitis underneath the arrays were main adverse events (AEs) reported in phase 3 GBM trials. The safety of TTFields was analyzed in two phase I-II studies in non-small-cell lung cancer (NSCLC) [EF-15, NCT00749346] and malignant pleural mesothelioma (MPM) [STELLAR, NCT02397928].
      PubDate: Sat, 13 Apr 2019 00:00:00 GMT
      DOI: 10.1093/annonc/mdz069.003
      Issue No: Vol. 30, No. Supplement_2 (2019)
       
  • 179PTreatment (tx) characteristics of patients (pts) with locally advanced
           or metastatic non-small cell lung cancer (NSCLC) receiving atezolizumab
           (atezo) monotherapy in US clinical practice
    • Authors: Frueh M; Rahma O, Pachynski R, et al.
      Abstract: Background: In the randomised Ph III OAK study, atezo (anti–PD-L1) significantly improved survival vs docetaxel, regardless of PD-L1 levels, and was approved by the FDA and EMA as 2L+ tx for advanced NSCLC. Given limited real-world data (RWD) on atezo in clinical practice, we describe here tx and characteristics of pts receiving atezo in clinical practice.
      PubDate: Sat, 13 Apr 2019 00:00:00 GMT
      DOI: 10.1093/annonc/mdz063.077
      Issue No: Vol. 30, No. Supplement_2 (2019)
       
  • 82TiPIMpower030: Phase III study evaluating neoadjuvant treatment of
           resectable stage II-IIIB non-small cell lung cancer (NSCLC) with
           atezolizumab (atezo) + chemotherapy
    • Authors: Peters S; Kim A, Solomon B, et al.
      Abstract: Background: A standard of care for resectable early-stage NSCLC is surgery alone or in combination with adjuvant or neoadjuvant platinum-based doublet chemotherapy (PT-DC). Still, 30%-70% of patients develop recurrence and die from disease progression, highlighting the need for more effective treatments. Atezo, an anti–programmed death-ligand 1 (PD-L1) antibody that restores anti-tumour immunity, has shown promising efficacy as monotherapy and in combination with chemotherapy in advanced NSCLC. It is hypothesised that the combination of atezo and PT-DC may provide clinical benefit in the neoadjuvant setting by enhancing cancer cell killing and eradicating micrometastases, reducing the risk of disease recurrence. The objective of IMpower030 (NCT03456063) is to evaluate the efficacy and safety of atezo in combination with PT-DC as neoadjuvant treatment for patients with resectable early-stage NSCLC.
      PubDate: Sat, 13 Apr 2019 00:00:00 GMT
      DOI: 10.1093/annonc/mdz064.014
      Issue No: Vol. 30, No. Supplement_2 (2019)
       
  • 163PImmuno-oncological treatment and tumor load in non-small cell lung
           cancer (NSCLC): Case-control analysis of overall survival (OS) in routine
           clinical practice
    • Authors: Faehling M; Schwenk B, Kopp M, et al.
      Abstract: Background: Immuno-oncological (IO) therapies such as PD-1 and PD-L1-antibodies have been introduced in the treatment of advanced NSCLC since 2015 based on randomized trials showing unprecedented advantages in OS with hazard ratios (HR) often between 0.5 and 0.6. The impact of these treatments on survival in routine clinical practice and the role of tumor load have not been studied.
      PubDate: Sat, 13 Apr 2019 00:00:00 GMT
      DOI: 10.1093/annonc/mdz063.061
      Issue No: Vol. 30, No. Supplement_2 (2019)
       
  • 90PReal-world treatment patterns, clinical practice and outcomes for
           locally advanced, non resectable, non-small cell lung cancer from the
           French ESME Lung database
    • Authors: Girard N; Pérol M, Simon G, et al.
      Abstract: Background: Approximately 30% of patients (pts) with non-small-cell lung cancer (NSCLC) are diagnosed with locally advanced disease, which is often unresectable. The historical standard of care (SoC) has been platinum-based chemoradiotherapy (CRT), based on data from clinical trials conducted in selected populations. As immunotherapy is being integrated in the treatment strategy, real-world evidence aiming at understanding the current management of those patients is missing.
      PubDate: Sat, 13 Apr 2019 00:00:00 GMT
      DOI: 10.1093/annonc/mdz067.006
      Issue No: Vol. 30, No. Supplement_2 (2019)
       
  • 64PTiming of treatment with concurrent chemoradiotherapy (CRT) and impact
           on progression free survival (PFS) in limited stage small cell lung cancer
           (LSSCLC)
    • Authors: McSorley L; Goggin C, Elhadi N, et al.
      Abstract: Background: SCLC is an aggressive cancer subtype, with early metastatic spread and poor prognosis. We review Irish patient outcomes, outside of a clinical trial setting, to determine if patients who commenced radiotherapy (RT) within 30days of chemotherapy (CT) had a longer PFS.
      PubDate: Sat, 13 Apr 2019 00:00:00 GMT
      DOI: 10.1093/annonc/mdz071.004
      Issue No: Vol. 30, No. Supplement_2 (2019)
       
  • 22PPaclitaxel/ carboplatin/ bevacizumab in non-small cell lung cancer
           patients induces peripheral effector CD8 T cell proliferation that could
           be prone for treatment with checkpoint inhibitors
    • Authors: Dumoulin D; de Goeje P, Poncin M, et al.
      Abstract: Background: Checkpoint inhibitors targeting programmed death receptor (PD)-1 or PD-ligand 1 (PD-L1) became the cornerstone in the treatment of advanced NSCLC. Several phase III trials showed a better overall survival by treating with combination chemotherapy and checkpoint inhibition, suggesting that addition of chemotherapy increased the response to checkpoint inhibitors. Recently, peripheral blood biomarkers such as Ki67+PD-1+CD8 cells were found to be predictive for clinical outcome with PD-1 treatment. Knowing more about immune modulatory capacities of chemotherapy can help us to design better treatment strategies. We investigated the immune-modulatory effects of paclitaxel/carboplatin/bevacizumab (PCB), focusing on known immune populations associated with response to checkpoint inhibitors in peripheral blood.
      PubDate: Sat, 13 Apr 2019 00:00:00 GMT
      DOI: 10.1093/annonc/mdz073.001
      Issue No: Vol. 30, No. Supplement_2 (2019)
       
  • 36PCan a BALF profile distinguish hot vs cold lung tumors'
    • Authors: Domagala-Kulawik J; Dziedzic D, Polubiec-Kownacka M, et al.
      Abstract: Background: Immunotherapy brings evident benefits to lung cancer patients. However, the answer to this treatment is highly individualized and seems to be better in ‘hot’ tumors than in ’cold’ ones. The vast majority of lung cancers are in their advanced stages at recognition, therefore the access to large fragments of tumor tissue and tumor environment is limited. The results of our previous studies showed the usefulness of bronchoalveolar lavage fluid (BALF) examination in the evaluation of immune status in a lung tumor site. The aim of this study was to assess if BALF may reflect the signs of ‘hot’ vs. ‘cold’ tumors.
      PubDate: Sat, 13 Apr 2019 00:00:00 GMT
      DOI: 10.1093/annonc/mdz073.015
      Issue No: Vol. 30, No. Supplement_2 (2019)
       
  • 121PRisk of not receiving second-line therapy is high in EGFR mt+
           patients: Real-world data of certified lung cancer centers on treatment
           sequence in EGFR mt+ patients
    • Authors: Roeper J; Lueers A, Falk M, et al.
      Abstract: Background: Recently FLAURA study demonstrated significant PFS and numeric OS benefit for Osimertinib 1st line vs. 1st gen. TKI’s Erlotinib/Gefitinib. The number of pts switching from 1st gen. to 3rd gen. TKI (30%) appeared to be low and it is questionable whether these data represent real world sequencing treatment patterns. Therefore, we investigated the sequence pattern, i.e. the percentage of 2nd line therapy in EGFR mt+ pts in 3 certified lung cancer centers in Germany.
      PubDate: Sat, 13 Apr 2019 00:00:00 GMT
      DOI: 10.1093/annonc/mdz063.019
      Issue No: Vol. 30, No. Supplement_2 (2019)
       
  • 141PEffect of central nervous system (CNS) metastases in a real-world
           multicenter cohort study of Spanish ALK-positive non-small cell lung
           cancer (NSCLC) patients (p)
    • Authors: Angelats L; Garcia Campelo M, Bernabe Caro R, et al.
      Abstract: Background: CNS is a common site of metastases in patients with ALK-positive NSCLC. CNS metastases are associated with a number of deleterious effects, such as reduction in quality of life. However, the relationship between brain metastases and prognosis remains unclear. We aimed to evaluate the effect of CNS metastases on overall survival (OS) in a multicenter cohort of Spanish ALK-positive NSCLC patients diagnosed between 2008 and 2017.
      PubDate: Sat, 13 Apr 2019 00:00:00 GMT
      DOI: 10.1093/annonc/mdz063.039
      Issue No: Vol. 30, No. Supplement_2 (2019)
       
  • 198PEfficacy of 150 kHz tumor treating fields (TTFields) and cisplatin
           or pemetrexed for the treatment of mesothelioma cells in vitro
    • Authors: Weinberg U; Munster M, Gotlib K, et al.
      Abstract: Background: Malignant pleural mesothelioma (MPM) is a rare and aggressive thoracic cancer that has been strongly linked to asbestos exposure. The standard of care treatment for unresectable mesothelioma is cisplatin plus pemetrexed chemotherapy, which offers modest outcomes. Thus, there is an urgent need to identify more effective treatments for mesothelioma patients. Tumor Treating Fields (TTFields) therapy is an effective anti-neoplastic treatment modality delivered via noninvasive application of low intensity, intermediate frequency, alternating electric fields. We explored the potential use of TTFields alone and in combination with cisplatin or pemetrexed as a treatment for mesothelioma.
      PubDate: Sat, 13 Apr 2019 00:00:00 GMT
      DOI: 10.1093/annonc/mdz069.002
      Issue No: Vol. 30, No. Supplement_2 (2019)
       
  • 178PFeasibility of O-(2-[18F]fluoroethyl)-L-tyrosine (FET) PET for
           treatment monitoring of brain metastases in lung cancer patients
    • Authors: Abdulla D; Ruge M, Scheffler M, et al.
      Abstract: Background: Brain metastases (BMs) occur frequently in patients with advanced lung cancer. So far, intracranial efficacy of systemic lung cancer treatment is nearly unpredictable. Contrast-enhanced magnetic resonance imaging (MRI) is considered gold standard for response assessment but lacks potential to discriminate between malignant or active tumor lesions from benign or postinflammatory signal alterations. O-(2- [18F]fluoroethyl)-L-tyrosine (FET)-positron emission tomography (PET) has shown additional diagnostic value over standard MRI in glioma patients. We set out this analysis to determine the feasibility of FET PET in lung cancer patients.
      PubDate: Sat, 13 Apr 2019 00:00:00 GMT
      DOI: 10.1093/annonc/mdz063.076
      Issue No: Vol. 30, No. Supplement_2 (2019)
       
  • 162PMonitoring of blood serum amyloid (SAA) to predict outcome of
           first-line pembrolizumab (P) in patients (pts) with advanced non-small
           cell lung cancer (ANSCLC)
    • Authors: Di Noia V; D’Argento E, Vita E, et al.
      Abstract: Background: In melanoma pts, SAA inhibits the anti-tumor immune response by the expansion of IL-10-secreting neutrophils. We previously found that baseline high SAA was associated with early progressive disease (PD) in small cohort of ANSCLC pts receiving up-front P. Here we explored the relationship between dynamic monitoring of SAA and survival outcomes in an enlarged cohort.
      PubDate: Sat, 13 Apr 2019 00:00:00 GMT
      DOI: 10.1093/annonc/mdz063.060
      Issue No: Vol. 30, No. Supplement_2 (2019)
       
  • 89PTreatment patterns and long-term survival for unresected stage III
           non-small cell lung cancer patients: A nationwide register study in
           Denmark
    • Authors: Green A; Olsen K, Bliddal M, et al.
      Abstract: Background: Patients with stage III non-small cell lung cancer (NSCLC) is a heterogeneous population with resectable or unresectable tumors. Current standard of care for unresectable disease has since long been either curatively intended chemoradiotherapy (CRT) followed by active surveillance, or palliative treatment for CRT ineligible patients. Recently, published data have shown survival benefit of CRT followed by immunotherapy (durvalumab). The aim was to investigate long-term survival, treatment patterns, and characteristics for unresected stage III NSCLC patients in a real-life setting.
      PubDate: Sat, 13 Apr 2019 00:00:00 GMT
      DOI: 10.1093/annonc/mdz067.005
      Issue No: Vol. 30, No. Supplement_2 (2019)
       
  • 1OImpact of MET variants on PD-L1 expression in pleomorphic lung carcinoma
    • Authors: Januszewski A; Zhang Y, Chang W, et al.
      Abstract: Background: Pleomorphic Lung Carcinoma (PC) is a rare subtype of NSCLCs poorly responsive to systemic therapy. It is a heterogenous tumour with both epithelial and sarcomatoid components. MET variants are targetable aberrations and have recently been reported to be more frequent in PCs. The relationship between MET and PD-L1 expression is not well understood. We determined PD-L1 expression in PCs and its relationship with MET variants.
      PubDate: Sat, 13 Apr 2019 00:00:00 GMT
      DOI: 10.1093/annonc/mdz072
      Issue No: Vol. 30, No. Supplement_2 (2019)
       
  • 81PHigher PD-L1 expression correlates with lymphocyte infiltration in
           early non-small cell lung cancer
    • Authors: Rocha P; Rodrigo M, Moliner L, et al.
      Abstract: Background: Patients with advanced NSCLC (Non-small cell lung cancer) benefit from ICIs (immune checkpoint inhibitors) as part of their treatment strategy. This benefit might also be observed in earlier stages. The aim of our work was to characterize the immune contexture of early NSCLC and assess the impact on outcome of immune biomarkers.
      PubDate: Sat, 13 Apr 2019 00:00:00 GMT
      DOI: 10.1093/annonc/mdz064.013
      Issue No: Vol. 30, No. Supplement_2 (2019)
       
  • 35PClinicopathological characteristics with genetic profiling and
           prognostic analysis of primary lymphoepithelioma-like carcinoma in Chinese
           south-eastern population
    • Authors: Shen Y; Hu F, Zhang B, et al.
      Abstract: Background: Primary lymphoepithelioma-like carcinoma (LELC) is a rare form of lung cancer, since genetic alternations participate in the carcinogenesis in lung cancer, whether critical driver genes such as ROS1 fusion, anaplastic lymphoma kinase (ALK) rearrangement and epidermal growth factor receptor (EGFR) mutation play roles in LELC remains unclear.
      PubDate: Sat, 13 Apr 2019 00:00:00 GMT
      DOI: 10.1093/annonc/mdz073.014
      Issue No: Vol. 30, No. Supplement_2 (2019)
       
  • 120OThromboembolic events in advanced non-small cell lung cancer
    • Authors: Srinivasalu V; Subramaniam N, Raghuram S, et al.
      Abstract: Background: Cancer is a prothrombotic condition and its treatment is often complicated in the presence of thromboembolisms (TE) which adds to its morbidity and mortality. We aimed to assess the incidence of TE’s in patients with NSCLC treated at our institute.
      PubDate: Sat, 13 Apr 2019 00:00:00 GMT
      DOI: 10.1093/annonc/mdz063.018
      Issue No: Vol. 30, No. Supplement_2 (2019)
       
  • 63PReal-life experience with the implementation of DLL3 staining and the
           subsequent treatment with rovalpituzumab tesirine in heavily pretreated
           SCLC patients
    • Authors: Hochmair M; Weinlinger C, Fabikan H, et al.
      Abstract: Background: Around 15% of newly diagnosed lung cancer patients are characterized as SCLC mostly with extensive stage disease. While SCLC may be responsive to 1st or 2nd line chemotherapy, there is no approved drug for the 3rd line with guidelines recommending best supportive care. Rovalpituzumab Teserine (Rova-T) is a novel first–in-class antibody-drug conjugate and targets the delta-like protein 3 (DLL3), a newly discovered target highly expressed in SCLC and other high-grade neuroendocrine carcinomas. ROVA-T showed an encouraging single-agent anti-tumor activity and manageable safety profile in Phase 1 and 2 studies. The present study is a retrospective analysis to evaluate DLL3 testing and real-life experience with ROVA-T for patients with an unmet medical need after failure of at least 2 systemic treatments.
      PubDate: Sat, 13 Apr 2019 00:00:00 GMT
      DOI: 10.1093/annonc/mdz071.003
      Issue No: Vol. 30, No. Supplement_2 (2019)
       
  • 140PBrigatinib experience on the ALK project
    • Authors: Gomes F; Tokaca N, Yip K, et al.
      Abstract: Background: The ALK Project established a network across the UK with the aim to analyse treatment patterns/outcomes and promote collaborations and research. The treatment pathway for ALK+ patients has been revolutionised in recent years.
      PubDate: Sat, 13 Apr 2019 00:00:00 GMT
      DOI: 10.1093/annonc/mdz063.038
      Issue No: Vol. 30, No. Supplement_2 (2019)
       
  • 197PEffect of surgical treatment on the survival in patients with
           malignant pleural mesothelioma
    • Authors: Baez-Saldana R; Marmolejo-Torres M, Iñiguez-García M, et al.
      Abstract: Background: In patients with malignant pleural mesothelioma (MPM) chemotherapy is the only treatment modality that has been shown to improve survival. Surgery, by either pleurectomy/decortication (P/D) or extrapleural pneumonectomy (EPP) can be an option of treatment in patients with early stage disease and good functional status, nevertheless, this modality remains questionable. The aim of this study was to evaluate the effect of surgical treatment on the survival in patients with MPM.
      PubDate: Sat, 13 Apr 2019 00:00:00 GMT
      DOI: 10.1093/annonc/mdz069.001
      Issue No: Vol. 30, No. Supplement_2 (2019)
       
  • 20PAtypical hyperplasia of bronchial epithelial cells induced by chronic
           exposure to PM 2.5 in mice
    • Authors: Hou T; Chen Q.
      Abstract: Background: Air pollution is still a major environmental problem affecting the health of the respiratory system. Studies have confirmed that air pollution is closely related to the occurrence of lung cancer. Air pollution (mainly PM2.5) has been classified as a carcinogen by the International Agency for Research on Cancer. Previous evidence of the relationship between PM2.5 and lung cancer mostly comes from countries with low PM2.5 exposure level. Exposure to fine particulate matter (PM2.5) may increase the risk of lung cancer, but the underlying mechanism is still unclear.There is no direct evidence that PM2.5 can directly induce lung cancer .The aim of our study was to investigate the atypical hyperplasia of bronchial epithelial cells induced by chronic exposure to PM2.5 in mice and the possible mechanism of PM2.5 in the pathogenesis of severe atypical hyperplasia.
      PubDate: Sat, 13 Apr 2019 00:00:00 GMT
      DOI: 10.1093/annonc/mdz072.018
      Issue No: Vol. 30, No. Supplement_2 (2019)
       
  • 161PTumor mutational burden assessed by a targeted NGS assay predicts
           clinical benefit from immune checkpoint inhibitors in non-small cell lung
           cancer
    • Authors: Jermann P; Alborelli I, Leonards K, et al.
      Abstract: Background: In non-small cell lung cancer (NSCLC) immune checkpoint inhibitors (ICIs) significantly improve progression-free survival (PFS) and objective response rate. Biomarkers capable of predicting response to ICIs are highly desired. Assessment of tumor mutational burden (TMB) by whole-exome sequencing has been associated with outcome in patients treated with ICIs. Recently, being more suited for clinical applications, targeted sequencing has also proven its ability to reliably assess TMB. Our study is the first to evaluate the predictive power of TMB measured through the Oncomine Tumor Mutational Load (TML - Thermo Fisher Scientific) assay in 64 NSCLC patients treated with ICIs.
      PubDate: Sat, 13 Apr 2019 00:00:00 GMT
      DOI: 10.1093/annonc/mdz063.059
      Issue No: Vol. 30, No. Supplement_2 (2019)
       
  • 177PReal-world experience of ALK positive NSCLC from India
    • Authors: Malhotra M; Noronha V, Joshi A, et al.
      Abstract: Background: ALK gene rearranged lung cancer is a rare subset of NSCLC. However, treatment with ALK inhibitors leads to a drastic improvement in outcomes. In this study, we have audited the outcomes of patients with ALK-rearranged NSCLC at our institute.
      PubDate: Sat, 13 Apr 2019 00:00:00 GMT
      DOI: 10.1093/annonc/mdz063.075
      Issue No: Vol. 30, No. Supplement_2 (2019)
       
  • 87PTime-series of peripheral blood biomarkers as biomarkers for
           immunotherapy in advanced non-small cell lung cancer (aNSCLC) patients
    • Authors: Prelaj A; Rebuzzi S, Pizzutilo P, et al.
      Abstract: Background: Immune-checkpoint inhibitors (ICIs) as second-line therapy showed an overall survival (OS) benefit, but only 18-20% of aNSCLC patients respond with a median progression-free survival (mPFS) of 2-4 months. The identification of biomarkers to select patients most likely to benefit from ICIs is still an unmet need in clinical practice.
      PubDate: Sat, 13 Apr 2019 00:00:00 GMT
      DOI: 10.1093/annonc/mdz067.004
      Issue No: Vol. 30, No. Supplement_2 (2019)
       
  • 80PHigh blood platelets levels (BPL): A prognostic factor in patients with
           early or locally advanced non-small cell lung cancer (NSCLC)
    • Authors: Cordoba Ortega J; Salud A, Morales S, et al.
      Abstract: Background: Patients with high blood platelets levels (BPL) have been reported to attenuate the efficacy of platinum-based chemotherapy and to have a worse prognosis when treated with surgery and postoperative adjuvant chemotherapy. This study describes a series of sample tumors from patients with clinically confirmed lung cancer.
      PubDate: Sat, 13 Apr 2019 00:00:00 GMT
      DOI: 10.1093/annonc/mdz064.012
      Issue No: Vol. 30, No. Supplement_2 (2019)
       
  • 62PExternal validation of a survival score for limited stage small cell
           lung cancer treated with chemoradiotherapy
    • Authors: Käsmann L; Abdo R, Taugner J, et al.
      Abstract: Background: In 2016, a survival score for limited stage small cell lung cancer (LS-SCLC) patients was developed to characterize prognostic sub-groups who underwent multimodal treatment. Herein, we validate the score in an independent external patient cohort.
      PubDate: Sat, 13 Apr 2019 00:00:00 GMT
      DOI: 10.1093/annonc/mdz071.002
      Issue No: Vol. 30, No. Supplement_2 (2019)
       
  • 139PReal-world immuno-oncology (IO) therapy treatment patterns and
           outcomes in patients with anaplastic lymphoma kinase positive (ALK+)
           non-small cell lung cancer (NSCLC) in the United States
    • Authors: Pan X; Lin M, Yin Y, et al.
      Abstract: Background: Cancer immunotherapies are new treatment options in advanced NSCLC. Evidence of IO therapy efficacy in tumors with activating mutations, such as ALK rearrangements, is lacking. This retrospective study describes the characteristics of ALK+ NSCLC patients treated with IO therapy and assesses treatment outcomes (time to treatment discontinuation, real-world progression-free survival [rwPFS], overall survival [OS]).
      PubDate: Sat, 13 Apr 2019 00:00:00 GMT
      DOI: 10.1093/annonc/mdz063.037
      Issue No: Vol. 30, No. Supplement_2 (2019)
       
  • 119OEfficacy and safety of nintedanib + docetaxel in lung adenocarcinoma
           patients (pts) following treatment with immune checkpoint inhibitors
           (ICIs): First results of the ongoing non-interventional study (NIS)
           VARGADO
    • Authors: Grohe C; Gleiber W, Haas S, et al.
      Abstract: Background: Nintedanib (Vargatef®) is an oral triple angiokinase inhibitor of VEGF-, PDGF- and FGF-receptors approved in the EU and other countries for treatment of locally advanced or metastatic NSCLC of adenocarcinoma histology in combination with docetaxel after 1st line chemotherapy. Data are sparse regarding efficacy and safety of nintedanib in NSCLC pts who had been treated with ICIs.
      PubDate: Sat, 13 Apr 2019 00:00:00 GMT
      DOI: 10.1093/annonc/mdz063.017
      Issue No: Vol. 30, No. Supplement_2 (2019)
       
  • 34PImpacts of HDAC2 inhibition on lung cancer treatment
    • Authors: Yeh Y; Wu C, Lai J, et al.
      Abstract: Background: Approximately 80% of lung cancer is non-small cell lung cancer (NSCLC) with a median survival time of 8 to 10 months. It is critical and urgent to find the effective interventions for patients suffering from NSCLC. Histone deacetylase 2 (HDAC2) is increasingly associated with development of several solid tumors. However, its role in lung cancer remained mostly lacking.
      PubDate: Sat, 13 Apr 2019 00:00:00 GMT
      DOI: 10.1093/annonc/mdz073.013
      Issue No: Vol. 30, No. Supplement_2 (2019)
       
  • 189OEGFR-TKIs plus bevacizumab demonstrated survival benefit than
           EGFR-TKIs alone in EGFR-mutant NSCLC patients with multiple brain
           metastases
    • Authors: Jiang T; Zhou C.
      Abstract: Background: Brain metastasis (BM) is the intractable disease in patients (Pts) with advanced non-small-cell lung cancer (NSCLC). Previous studies reported that EGFR-TKI plus bevacizumab (Ebe) could result in a significant prolongation of progression-free survival (PFS) than EGFR-TKI (E) alone. This study aimed to investigate whether Ebe could provide survival benefit than E alone in EGFR-mutant NSCLC Pts with BM.
      PubDate: Sat, 13 Apr 2019 00:00:00 GMT
      DOI: 10.1093/annonc/mdz068
      Issue No: Vol. 30, No. Supplement_2 (2019)
       
  • 19PFOXP3Δ3, the major isoform of FOXP3, promotes proliferation,
           migration, and invasion in non-small cell lung cancer
    • Authors: Jia H; Qi H, Peng J, et al.
      Abstract: Background: Increasing evidence has shown that FOXP3 is not only expressed in immune cells but also in tumor cells. However, the results of tumor FOXP3 is inconsistent and even the opposite. Unlike mice, humans express multiple isoforms of FOXP3. However, the expression and role of FOXP3 isoforms in cancers are still largely unknown. The role of FOXP3 and FOXP3Δ3 in NSCLC remains unclear.
      PubDate: Sat, 13 Apr 2019 00:00:00 GMT
      DOI: 10.1093/annonc/mdz072.017
      Issue No: Vol. 30, No. Supplement_2 (2019)
       
  • 160PEPSILoN score: Validation cohort of a prognostic score in advanced
           non-small cell lung cancer (aNSCLC) patients treated with immunotherapy
    • Authors: Prelaj A; Lo Russo G, Signorelli D, et al.
      Abstract: Background: Despite the benefit in overall survival (OS), only 18-20% of aNSCLC patients (pts) respond to immunotherapy (IO) in second-line (2nd) with a median progression-free survival (mPFS) of 2-4 months (mo). We previously reported the role of EPSILoN score (Ecog-Ps, Smoke, lIver, Ldh, Nlr) as a clinical and biochemical prognostic score of survival in 154 pts treated with 2nd IO. In this study we aim to validate the EPSILoN score in a different patient population group treated with IO in the same setting.
      PubDate: Sat, 13 Apr 2019 00:00:00 GMT
      DOI: 10.1093/annonc/mdz063.058
      Issue No: Vol. 30, No. Supplement_2 (2019)
       
  • 86OThe effect of prophylactic cranial irradiation (PCI) for young stage
           III NSCLC patients: Subgroup analyses of the NVALT-11/DLCRG-02 study
    • Authors: Witlox W; Ramaekers B, Groen H, et al.
      Abstract: Background: The NVALT-11/DLCRG-02 phase III study compared PCI to observation after chemo-radiotherapy (RT) for stage III NSCLC and showed a significant decrease in the cumulative incidence of symptomatic brain metastases (BM) in the PCI arm at two years (7% vs 27% [HR 0.23]). We here performed exploratory subgroup analyses.
      PubDate: Sat, 13 Apr 2019 00:00:00 GMT
      DOI: 10.1093/annonc/mdz067.003
      Issue No: Vol. 30, No. Supplement_2 (2019)
       
  • 138PPD-L1 confers primary resistance to EGFR-TKI in EGFR mutant non-small
           cell lung cancer via inducing EMT phenotype
    • Authors: Zhang Y; Liu T, Zeng Y, et al.
      Abstract: Background: There were approximately 30% of patients with epidermal growth factor receptor (EGFR)-activating mutations do not respond to EGFR- tyrosine kinase inhibitors (TKIs) (primary resistance). However, little is known about the molecular mechanism involved in primary resistance to EGFR-TKIs in EGFR-mutant non-small-cell lung cancer (NSCLC). Programmed death ligand-1 (PD-L1) (B7-H1, CD274) is an important immune co-signaling molecule from the B7/CD28 family, it not only negatively regulates T cell functions through its PD-1 and CD80 interactions, but also plays important regulatory roles in intracellular functions and leads to acquired resistance to EGFR-TKIs in NSCLC. Here, we investigated that mechanistic role of PD-L1 in primary resistance to EGFR-TKIs in EGFR-mutant NSCLC.
      PubDate: Sat, 13 Apr 2019 00:00:00 GMT
      DOI: 10.1093/annonc/mdz063.036
      Issue No: Vol. 30, No. Supplement_2 (2019)
       
  • 79PTissue microarray analysis on prognostic value of coexpression of RUNX3
           and trimethylated histone H3 lysine 27 in surgically resected patients
           with stage I non-small cell lung cancer
    • Authors: Chen X; Deng Y, Shi Y.
      Abstract: Background: Lung cancer is still the leading cause of cancer-related deaths in both sexes in China and worldwide. Although many surgically resected patients shared the same histology and pathologic TNM stage, their prognosis had varied a lot. For within the stage-Ipatients who had received radical surgery of lung cancer, nearly one-third of them suffered from postoperative relapse or distant metastasis. In the present study, we sought to investigate the potential interrelationships of expression of RUNX3, H3K27me3 and its methyltransferase EZH2 in NSCLC patients, their correlation with clinicopathologic parameters, and the prognostic significance as well.
      PubDate: Sat, 13 Apr 2019 00:00:00 GMT
      DOI: 10.1093/annonc/mdz064.011
      Issue No: Vol. 30, No. Supplement_2 (2019)
       
  • 61PValue of post-radiotherapy for limited stage small cell lung cancer on
           basis of a prognostic scoring model
    • Authors: Yu J; Ouyang W, Hu J, et al.
      Abstract: Background: Small cell lung carcinoma (SCLC) rarely underwent surgical treatment. The aim of the study was to investigate the value of postoperative radiotherapy for limited stage small cell lung cancer based on a prognostic scoring model.
      PubDate: Sat, 13 Apr 2019 00:00:00 GMT
      DOI: 10.1093/annonc/mdz071.001
      Issue No: Vol. 30, No. Supplement_2 (2019)
       
  • 118O Blood tumor mutational burden as a predictor of clinical benefit in
           non-small cell lung cancer patients treated with docetaxel: Secondary
           analysis of the OAK and POPLAR randomized clinical trials
    • Authors: Nie W; Qian J, Han B.
      Abstract: Background: Blood-based tumor mutational burden (bTMB), which is measured by targeted next-generation sequencing (NGS) using cell-free DNA (cfDNA), shows a positive correlation with tissue-based TMB and is a predictive biomarker for non-small cell lung cancer (NSCLC) patients receiving atezolizumab. However, the role of bTMB in other treatment settings, such as chemotherapy, is unknown. We hypothesized that advanced NSCLC patients with low bTMB would derive more benefit from chemotherapy.
      PubDate: Sat, 13 Apr 2019 00:00:00 GMT
      DOI: 10.1093/annonc/mdz063.016
      Issue No: Vol. 30, No. Supplement_2 (2019)
       
  • 195TiPPhase III METIS study: Tumor treating fields (150 kHz) and
           radiosurgery for supra- and/or infratentorial brain metastases (1-10) from
           non-small cell lung cancer (NSCLC)
    • Authors: Mehta M; Gondi V, Ahluwalia M, et al.
      Abstract: Background: Tumor Treating Fields (TTFields) are non-invasive, loco-regional, anti-mitotic treatment modality comprising low intensity alternating electric fields. TTFields has demonstrated efficacy in non-small cell lung cancer (NSCLC) in in vitro and in vivo models, and in a phase I/II clinical study. TTFields treatment to the brain was safe and extended overall survival in newly-diagnosed glioblastoma. This prospective, multicenter study [NCT02831959] investigated the efficacy, safety and neurocognitive outcomes of TTFields in NSCLC patients with brain metastases.
      PubDate: Sat, 13 Apr 2019 00:00:00 GMT
      DOI: 10.1093/annonc/mdz068.005
      Issue No: Vol. 30, No. Supplement_2 (2019)
       
  • 159PInitial serum tumor marker dynamics predict progression-free and
           overall survival in single PD-1/PD-L1 inhibitor treated advanced NSCLC
    • Authors: Lang D; Horner A, Brehm E, et al.
      Abstract: Background: Routine measurement of serum tumor markers (STM) is not recommended in advanced non-small cell lung cancer (NSCLC). However, immune checkpoint inhibitor (ICI) treated patients may initially present with indeterminate radiological response, demanding additional biomarkers aiding clinical decisions.
      PubDate: Sat, 13 Apr 2019 00:00:00 GMT
      DOI: 10.1093/annonc/mdz063.057
      Issue No: Vol. 30, No. Supplement_2 (2019)
       
  • 18PImmunohistochemical expression of PD-L1 in early and late stage
           non-small cell lung cancer: Correlation with clinicopathological and
           molecular features
    • Authors: Kokkotou E; Rapti V, Grapsa D, et al.
      Abstract: Background: The immunohistochemical expression of PD-L1 protein has been evaluated as a predictor of prognosis and response to immunotherapy, with controversial results. We herein aimed to further study its clinical relevance in patients with non-small cell lung cancer (NSCLC).
      PubDate: Sat, 13 Apr 2019 00:00:00 GMT
      DOI: 10.1093/annonc/mdz072.016
      Issue No: Vol. 30, No. Supplement_2 (2019)
       
  • 176PReal-world treatment patterns for metastatic non-small cell lung
           cancer at IRST Italy
    • Authors: Altini M; Massa I, Balzi W, et al.
      Abstract: Background: This study sought to describe treatment patterns in terms of real world first-line (1L) and second-line (2L) treatment of metastatic non-small cell lung cancer (NSCLC) prior to the availability of Immunotherapies (IOs) in Italy.
      PubDate: Sat, 13 Apr 2019 00:00:00 GMT
      DOI: 10.1093/annonc/mdz063.074
      Issue No: Vol. 30, No. Supplement_2 (2019)
       
  • 85OPrevalence of programmed death ligand-1 (PD-L1) by demographic, disease
           and sample characteristics in unresectable, stage III NSCLC (PACIFIC)
    • Authors: Planchard D; Garassino M, Paz-Ares L, et al.
      Abstract: Background: PACIFIC (NCT02125461) was a randomised, placebo-controlled, phase 3 trial evaluating the immune checkpoint inhibitor durvalumab in patients (pts) with unresectable, Stage III non-small cell lung cancer (NSCLC) who did not have disease progression after concurrent chemoradiotherapy (cCRT). Both primary endpoints of progression-free survival and overall survival were met and significantly improved with durvalumab, with similar safety, versus placebo (Antonia et al, NEJM 2017; 2018). We report exploratory analyses of the prevalence of tumour PD-L1 expression by baseline pt, disease and sample characteristics and by response to prior treatment for pts in PACIFIC.
      PubDate: Sat, 13 Apr 2019 00:00:00 GMT
      DOI: 10.1093/annonc/mdz067.002
      Issue No: Vol. 30, No. Supplement_2 (2019)
       
  • 137PDetection and clinicopathologic features of ctDNA in T790M-positive
           advanced lung adenocarcinomas patients after failure of treatment with
           first- and second-generation EGFR-TKIs
    • Authors: He W; Zhou Z, Yu T, et al.
      Abstract: Background: We aimed to detect ctDNA in patients with advanced lung adenocarcinomas after failure of treatment with first- and second-generation EGFR-TKIs and to analyze it’s clinicopathologic features in a subset of patients harbouring the T790M mutation.
      PubDate: Sat, 13 Apr 2019 00:00:00 GMT
      DOI: 10.1093/annonc/mdz063.035
      Issue No: Vol. 30, No. Supplement_2 (2019)
       
  • 33PPrognostic value of CD8-positive tumor stroma-infiltrating lymphocytes
           and PD-L1 positive tumor cells at initial biopsy in patients with locally
           advanced NSCLC treated with chemoradiotherapy
    • Authors: Gennen K; Käsmann L, Eze C, et al.
      Abstract: Background: According to results of PACIFIC trial, immune checkpoint inhibitors (CPIs) are an integral part of the multimodal treatment approach for inoperable locally-advanced non-small cell lung cancer (LA-NSCLC). The purpose of this single-center study was to investigate a prognostic value of CD8-positive tumor stroma-infiltrating lymphocytes (TILs) and PD-L1 positive tumor cells at initial biopsy in patients treated with definitive chemoradiotherapy (CRT).
      PubDate: Sat, 13 Apr 2019 00:00:00 GMT
      DOI: 10.1093/annonc/mdz073.012
      Issue No: Vol. 30, No. Supplement_2 (2019)
       
  • 117ORacial disparities in characteristics and prognosis in Asian versus
           white patients receiving atezolizumab: An ancillary analysis of POPLAR and
           OAK studies
    • Authors: Qian J; Nie W, Lu J, et al.
      Abstract: Background: Racial differences in characteristics and prognosis of Asiatic and White patients receiving immunotherapy have not been well described.
      PubDate: Sat, 13 Apr 2019 00:00:00 GMT
      DOI: 10.1093/annonc/mdz063.015
      Issue No: Vol. 30, No. Supplement_2 (2019)
       
  • 78PLung resection for cancer in patients with heart disease: Management
           and postoperative outcome
    • Authors: Caushi F; Skenduli I, Hatibi A, et al.
      Abstract: Background: Patients with lung cancer sometimes presents with concomitant heart disease. That kind of patients represents a high risk group necessitating prompt diagnosis and treatment. As lung resection still is the treatment of choice for early stages of lung cancer, its feasibility depends on the severity of the cardiac impairment. The aim of this study was to analyze the results of lung resection in patients with heart disease in terms of 30 day postoperative mortality, hospital stay and 5 year survival.
      PubDate: Sat, 13 Apr 2019 00:00:00 GMT
      DOI: 10.1093/annonc/mdz064.010
      Issue No: Vol. 30, No. Supplement_2 (2019)
       
  • 42OImplementation of organized lung cancer screening program in Korea
    • Authors: Kim Y.
      Abstract: Background: Lung cancer is the leading cause of cancer mortality worldwide and has a low survival rate due to difficulties cocnerning early detection. The Korean Lung Cancer Screening demonstration project (K-LUCAS) was started in February 2017. K-LUCAS will assess the effectiveness, harm, and feasibility of lung cancer screening in order to implement a population-based screening program. K-LUCAS will evaluate the validation of the new standard of reporting form of low-dose computed tomography (LDCT) and the quality of lung cancer screening by a web-based network system using computer-aided nodule detection program (CAD).
      PubDate: Sat, 13 Apr 2019 00:00:00 GMT
      DOI: 10.1093/annonc/mdz070
      Issue No: Vol. 30, No. Supplement_2 (2019)
       
  • 17PREDOXI-miRNA of Keap1/Nrf2 axis in lung tumors
    • Authors: Fabrizio F; Sparaneo A, Castellana S, et al.
      Abstract: Background: Oxidative and electrophilic changes in cellular redox balance are mainly coordinated by the Keap1/Nrf2 axis and is strongly related to tumor progression, chemo- and radio-therapy resistance of cancer cells. In lung tumors this system is constitutively activated mainly by the loss of Keap1 or gain of Nrf2 functions due to point mutations in the key interacting domains of these two proteins. Beside of genetic lesions, Keap1/Nrf2 epigenetic abnormalities, as aberrant Keap1 promoter methylation and regulation by microRNAs were reported as emerging mechanisms of deregulation. Here we investigated the contribution of miRNA machinery on the modulations of Keap1/Nrf2 activity in lung tumors by analyzing panels of NSCLC and SCLC cell lines.
      PubDate: Sat, 13 Apr 2019 00:00:00 GMT
      DOI: 10.1093/annonc/mdz072.015
      Issue No: Vol. 30, No. Supplement_2 (2019)
       
  • 193PManagement of cN2 NSCLC patients treated with radical radiotherapy:
           Relapse with or without brain metastases
    • Authors: McKay F; Ansel S, Lowrie C, et al.
      Abstract: Background: The management and treatment of brain metastases (BM) is debated in NSCLC. SIGN guidelines state all cN2 patients should receive brain imaging prior to curative treatment. Furthermore NICE guidelines state those with a PS 0-1 should be offered palliative whole brain radiotherapy (RT) whilst the QUARTZ study recommends none. More recent advances in radiotherapy, surgery and chemotherapy may change this treatment paradigm. Therefore the aim of this study was to investigate the management of BM in a cN2 cohort of NSCLC patients treated with radical RT.
      PubDate: Sat, 13 Apr 2019 00:00:00 GMT
      DOI: 10.1093/annonc/mdz068.004
      Issue No: Vol. 30, No. Supplement_2 (2019)
       
  • 158PImmune-related adverse events (irAEs) in advanced non-small cell lung
           cancer (aNSCLC): Platelet-to-lymphocyte ratio (PLR) predicts the risk of
           development and relapse
    • Authors: Pavan A; Calvetti L, Dal Maso A, et al.
      Abstract: Background: Immune checkpoint inhibitors (ICIs) have radically changed the treatment of aNSCLC patients (pts). IrAEs are mainly reversible but they require timely recognition and management and may be potentially life-threatening. No predictive markers are available to predict the onset of irAEs and their risk of recurrence. Aim of the study was to evaluate the potential role of circulating markers in predicting the development of irAEs.
      PubDate: Sat, 13 Apr 2019 00:00:00 GMT
      DOI: 10.1093/annonc/mdz063.056
      Issue No: Vol. 30, No. Supplement_2 (2019)
       
  • 84OPhase I study of gefitinib (G) + durvalumab (D) for locally
           advanced/metastatic non-small cell lung cancer (NSCLC) harbouring
           epidermal growth factor receptor (EGFR) sensitising mutations
    • Authors: Creelan B; Yeh T, Kim S, et al.
      Abstract: Background: G and D have both shown efficacy in patients (pts) with NSCLC; G + D may improve durability of response.
      PubDate: Sat, 13 Apr 2019 00:00:00 GMT
      DOI: 10.1093/annonc/mdz067.001
      Issue No: Vol. 30, No. Supplement_2 (2019)
       
  • 136PCorrelation of molecular status and anatomic sites of metastases at
           diagnosis of EGFR positive non-small cell lung cancer (NSCLC): A single
           institution experience
    • Authors: Krpina K; Budimir B, Kukulj S, et al.
      Abstract: Background: A significant proportion of NSCLC patients carry mutations in the epidermal growth factor receptor (EGFR) kinase domain, in most cases with the presence of a deletion mutation in exon 19 or L858R point mutation. The aim of our analysis was to examine the patterns of metastatic spread in IV stage nsclc and whether it varies by EGFR mutation status.
      PubDate: Sat, 13 Apr 2019 00:00:00 GMT
      DOI: 10.1093/annonc/mdz063.034
      Issue No: Vol. 30, No. Supplement_2 (2019)
       
  • 15PTTF1 status in non-small cell lung cancer adenocarcinoma: A prognostic
           factor
    • Authors: Cordoba Ortega J; Salud A, Morales S, et al.
      Abstract: Background: Patients with thyroid transcription factor 1 (TTF1) negative lung adenocarcinoma (ADC) have been reported to have a worse prognosis and to lack epidermal growth factor receptor (EGFR) mutations. The aim of this study was to analyse the prognostic significance of TTFI status in a series of tumor samples from patients with clinically confirmed lung adenocarcinoma.
      PubDate: Sat, 13 Apr 2019 00:00:00 GMT
      DOI: 10.1093/annonc/mdz072.014
      Issue No: Vol. 30, No. Supplement_2 (2019)
       
  • 192PCharacterization and potential role of PD-L1 positive lung cancer stem
           cells in lymph nodes metastasis
    • Authors: Raniszewska A; Rutkowska E, Sokolowski R, et al.
      Abstract: Background: An immunotherapy was found to be effective in achieving long-term survival in some lung cancer patients and has emerged to searching for new immune biomarkers. It is suggested that lung cancer stem cells (LCSCs) are responsible for tumor initiation, maintenance and its metastatic potential. In our previous studies, we confirmed the presence of PD-L1 positive LCSCs (EPCAM+/CD133+) in metastatic lymph nodes (LNs). The aim of this study was to assess the presence of LCSCs in LNs aspirates using extended LCSCs markers and compare it with clinical data of patients.
      PubDate: Sat, 13 Apr 2019 00:00:00 GMT
      DOI: 10.1093/annonc/mdz068.003
      Issue No: Vol. 30, No. Supplement_2 (2019)
       
  • 116OHealth-related quality of life (HRQoL) of non-small cell lung cancer
           (NSCLC) patients treated with nivolumab in real-life: The EVIDENS study
    • Authors: Pérol M; Dixmier A, Barlesi F, et al.
      Abstract: Background: EVIDENS is an observational, prospective, multicenter cohort study following lung cancer patients initially treated with nivolumab between Oct 2016 and Nov 2017 in 146 French centers. Interim efficacy and safety results were consistent with those from nivolumab clinical trials. This analysis describes temporal changes in HRQoL.
      PubDate: Sat, 13 Apr 2019 00:00:00 GMT
      DOI: 10.1093/annonc/mdz063.014
      Issue No: Vol. 30, No. Supplement_2 (2019)
       
  • 157PPrognostic impact of the use of antibiotics in patients with advanced
           non-small cell lung cancer (NSCLC) receiving PD-(L)1 targeting monoclonal
           antibodies
    • Authors: Schett A; Rothschild S, Mauti L, et al.
      Abstract: Background: Anti-PD-(L)1 monoclonal antibodies (mAb) have changed the therapeutic landscape in patients with advanced NSCLC, still 35-40% of these patients derive no benefit from anti-PD-(L)1 mAb. Antibiotics alter gut microbiota diversity and composition, and may affects antitumor immune responses following immune checkpoint inhibitors (ICI) in NSCLC.
      PubDate: Sat, 13 Apr 2019 00:00:00 GMT
      DOI: 10.1093/annonc/mdz063.055
      Issue No: Vol. 30, No. Supplement_2 (2019)
       
  • 53PPulmonary tuberculosis: A hurdle to overcome for early lung cancer
           diagnosis in TB burden countries
    • Authors: Akter M; Ahmed S.
      Abstract: Background: Bangladesh is ranked 6th among the Tuberculosis high burden countries. Sometimes, pulmonary tuberculosis (PTB) mimics the early symptoms of lung cancer. Developing countries like Bangladesh, with limited diagnostic facilities, often misdiagnose early lung cancer as smear negative PTB. According to national guidelines for PTB, smear negative PTB is defined as the cases diagnosed on the basis of X-ray abnormalities or suggestive histology and extra pulmonary cases without laboratory confirmation. This observational study has been done to find out the ratio of misdiagnosis of lung cancer as Smear Negative PTB.
      PubDate: Sat, 13 Apr 2019 00:00:00 GMT
      DOI: 10.1093/annonc/mdz070.011
      Issue No: Vol. 30, No. Supplement_2 (2019)
       
  • 55ORadiogenomic signatures of NSCLC brain metastases: A potential
           non-invasive imaging marker for ALK mutation
    • Authors: Wadhwa S; Krishna.b G, Malhotra M, et al.
      Abstract: Background: NSCLC harbouring ALK rearrangement has a higher risk of developing brain metastases. Literature on MR Imaging radiogenomics (MRI-R) as predictors of ALK mutation is limited and less investigated. The aim of our study was to evaluate the semantic MRI-R parameters of NSCLC brain metastases and their correlation with ALK status.
      PubDate: Sat, 13 Apr 2019 00:00:00 GMT
      DOI: 10.1093/annonc/mdz066
      Issue No: Vol. 30, No. Supplement_2 (2019)
       
  • 77PThe prognostic impact of the international association for the study of
           lung cancer (IASLC) definitions on completeness of surgical resection for
           non-small cell lung cancer (NSCLC)
    • Authors: Gagliasso M; Cartia C, Maraschi A, et al.
      Abstract: Background: To reappraise the prognostic significance of the IASLC definitions of complete, uncertain, and incomplete resection in NSCLC surgery.
      PubDate: Sat, 13 Apr 2019 00:00:00 GMT
      DOI: 10.1093/annonc/mdz064.009
      Issue No: Vol. 30, No. Supplement_2 (2019)
       
  • 175PPermanent pleural catheter (PPC) for malignant pleural effusion (PE)
           in advanced non-small cell lung cancer (NSCLC)
    • Authors: Martinez Kareaga M; Urbieta-Macazaga N, Sanchez-Vieco C, et al.
      Abstract: Background: Pleural effusion (PE) is a relatively frequent complication in patients (p) with advanced NSCLC that causes refractory symptoms such as pain and dyspnea. These patients frequently need repeated thoracocentesis to relieve symptoms.
      PubDate: Sat, 13 Apr 2019 00:00:00 GMT
      DOI: 10.1093/annonc/mdz063.073
      Issue No: Vol. 30, No. Supplement_2 (2019)
       
  • 135P EGFR & PD L1: An (im)perfect union
    • Authors: Batra U; Sharma M, Jain P, et al.
      Abstract: Background: EGFR inhibitors are associated with durable responses in patients harboring EGFR mutations. Also, Immune checkpoint inhibitors are associated with higher response rates with increasing PDL1 levels. PDL1 positivity in EGFR mutant metastatic non small cell lung cancer(mNSCLC) is known to portend poor prognosis due to resistance to TKI. However, the data regarding the same is scarce. This study was done as a retrospective analysis of treated cases of EGFR mutant mNSCLC with PDL1 levels done on the archival biopsy (first biopsy) specimen, which was used for diagnosis.
      PubDate: Sat, 13 Apr 2019 00:00:00 GMT
      DOI: 10.1093/annonc/mdz063.033
      Issue No: Vol. 30, No. Supplement_2 (2019)
       
  • 14PThe characteristics of MET exon 14 skipping mutations in Chinese
           non-small cell lung cancer: A retrospective analysis
    • Authors: Zhu Y; Xu C, Wang W, et al.
      Abstract: Background: MET exon 14 skipping is a potential driver alteration in lung cancer targetable. Treatment with crizotinib can cause dramatic responses in patients whose cancers have MET exon 14 skipping. The current study was aiming to determine the clinical and pathological characteristics in non-small cell lung cancers (NSCLC).
      PubDate: Sat, 13 Apr 2019 00:00:00 GMT
      DOI: 10.1093/annonc/mdz072.013
      Issue No: Vol. 30, No. Supplement_2 (2019)
       
  • 191PAssessment of toxicity and clinical outcomes with SBRT in lung
           metastases: A single institute experience
    • Authors: Pareek V.
      Abstract: Background: Stereotactic body radiation therapy (SBRT) can help deliver a high biologically equivalent dose to the tumor volume in a small number of fractions with a steep dose fallout on surrounding healthy tissues. A retrospective analysis was performed on patients treated for lung oligo-metastatic disease from various histopathologies.
      PubDate: Sat, 13 Apr 2019 00:00:00 GMT
      DOI: 10.1093/annonc/mdz068.002
      Issue No: Vol. 30, No. Supplement_2 (2019)
       
  • 156PPeripheral blood biomarkers as prognostic factors for immunotherapy in
           advanced non-small cell lung cancer (aNSCLC) patients
    • Authors: Prelaj A; Rebuzzi S, Pizzutilo P, et al.
      Abstract: Background: Second-line immunotherapy showed an overall survival (OS) benefit, but only a low percentage of aNSCLC patients (pts) respond to therapy. The identification of new biomarkers to select patients for immunotherapy (IO) is a crucial topic. In our study we aim to investigate the role of peripheral blood biomarkers (PBBs) that can predict response and outcome in aNSCLC pts treated with IO.
      PubDate: Sat, 13 Apr 2019 00:00:00 GMT
      DOI: 10.1093/annonc/mdz063.054
      Issue No: Vol. 30, No. Supplement_2 (2019)
       
  • 32PExosomes in NSCLC: Analysis of its cargo as a source of biomarkers
    • Authors: Durendez-Saez E; Calabuig Fariñas S, Suarez C, et al.
      Abstract: Background: Exosomes are membranous vesicles around 40-130 nm secreted by cells, carrying key information to distant tissues. Exosomes have been detected in different types of clinical samples and may play a key role in NSCLC. They intervene in several processes such as angiogenesis, metastatic niche formation, immunosuppression; being relevant in stem cell differentiation. The main objective of this study was to analyze exosomal cargo from NSCLC cell lines and primary cultures under two conditions: suspension cultures with cancer stem cells features (3D tumorspheres) and adherent cultures (2D).
      PubDate: Sat, 13 Apr 2019 00:00:00 GMT
      DOI: 10.1093/annonc/mdz073.011
      Issue No: Vol. 30, No. Supplement_2 (2019)
       
  • 59PComparison of internal target volume delineation using CT datasets of
           four-dimensional computed tomography in lung cancer radiotherapy
    • Authors: Bushra S; Tibdewal A, Mummudi N, et al.
      Abstract: Background: Precise tumour volume delineation is a major challenge in lung cancer radiotherapy (RT) because of respiration induced motion. Four-dimensional computed tomography (4DCT) using maximum intensity projection (MIP) dataset is commonly used method to generate internal target volume (ITV). This study compared ITV generation by tumour delineation on MIP and on all phases of the respiratory cycle.
      PubDate: Sat, 13 Apr 2019 00:00:00 GMT
      DOI: 10.1093/annonc/mdz066.004
      Issue No: Vol. 30, No. Supplement_2 (2019)
       
  • 52PConcordance, decision impact, and satisfaction for a computerized
           clinical decision support system in treatment of lung cancer patients
    • Authors: Lee K; Felix W, Jackson G.
      Abstract: Background: Treatment options for lung cancer patients are progressing rapidly. A clinical decision support system (CDSS) which affords first-line treatment recommendations for cancer patients was implemented at Jupiter Medical Center, on March 1, 2017. This pilot analysis studied system performance and its impact on patients and providers.
      PubDate: Sat, 13 Apr 2019 00:00:00 GMT
      DOI: 10.1093/annonc/mdz070.010
      Issue No: Vol. 30, No. Supplement_2 (2019)
       
  • 115OAfatinib in EGFR TKI-naïve patients (pts) with locally
           advanced/metastatic NSCLC harbouring EGFR mutations: An interim analysis
           of a phase IIIB trial
    • Authors: Passaro A; Laktionov K, Poltoratskiy A, et al.
      Abstract: Background: First-line afatinib significantly improved progression-free survival (PFS) in pts with EGFR mutation-positive (EGFRm+) NSCLC (including uncommon mutations) vs chemotherapy (CT) in the LUX-Lung (LL) 3/6 trials (median 11.1 vs 6.9 mos; HR 0.58/11.0 vs 5.6 mos; HR 0.28) and vs gefitinib in LL7 (median 11.0 vs 10.9 mos; HR 0.73). However, in real-world (RW) practice CT remains a first-line choice. Here, we report an interim analysis of a Phase IIIb study of afatinib in treatment-naïve or CT pre-treated pts with EGFRm+ NSCLC, similar to RW practice.
      PubDate: Sat, 13 Apr 2019 00:00:00 GMT
      DOI: 10.1093/annonc/mdz063.013
      Issue No: Vol. 30, No. Supplement_2 (2019)
       
  • 76PEndobronchial surgery and photodynamic therapy for early central lung
           cancer treatment
    • Authors: Pirogov S; Telegina L, Sokolov V, et al.
      Abstract: Background: Development of endoscopic therapeutic methods for early central lung cancer.
      PubDate: Sat, 13 Apr 2019 00:00:00 GMT
      DOI: 10.1093/annonc/mdz064.008
      Issue No: Vol. 30, No. Supplement_2 (2019)
       
  • 134PMutational spectrum of acquired resistance to reversible versus
           irreversible EGFR tyrosine kinase inhibitors
    • Authors: Wagener-Ryczek S; Heydt C, Sueptitz J, et al.
      Abstract: Background: Mutational spectrum of acquired resistance to reversible versus irreversible EGFR tyrosine kinase inhibitors Over the past years, EGFR tyrosine kinase inhibitors (TKI) revolutionized treatment response. 1st-generation (reversible) EGFR TKI later the 2nd –generation irreversible EGFR TKI Afatinib was aimed to improve treatment response. Nevertheless, diverse resistance mechanisms develop within the first year of therapy. Here, we evaluate the prevalence of acquired resistance mechanisms towards reversible and irreversible EGFR TKI.
      PubDate: Sat, 13 Apr 2019 00:00:00 GMT
      DOI: 10.1093/annonc/mdz063.032
      Issue No: Vol. 30, No. Supplement_2 (2019)
       
  • 13PThe micro-environmental cross talk between mast cells and lung cancer
           cells through cell-to-cell contact
    • Authors: Shemesh R; Gorzalczany Y, Sagi-Eisenberg R, et al.
      Abstract: Background: Mast cells (MCs) are key effectors in allergic reactions, but are also involved in tissue remodeling, wound healing and protection against pathogens. MCs infiltrate tumors and their number within the tumor microenvironment in certain cancer types, such as lung cancer, have been correlated with poor prognosis. The nature of crosstalk between lung cancer and MCs remain poorly resolved. In this study, we investigated the activation patterns within the MCs following cell-to-cell contact with lung cancer cells showing CD73 involvement.
      PubDate: Sat, 13 Apr 2019 00:00:00 GMT
      DOI: 10.1093/annonc/mdz072.012
      Issue No: Vol. 30, No. Supplement_2 (2019)
       
  • 190PERGR-TKIs combined with chemotherapy delays intracranial progression
           in EGFR-mutant lung adenocarcinoma patients
    • Authors: Li C; Zhang B, Guo J, et al.
      Abstract: Background: The aim of this study was to evaluate if the combination of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) plus chemotherapy could delay the presence and decrease the incidence of brain metastases (BM) in patients with EGFR-mutant advanced lung adenocarcinoma.
      PubDate: Sat, 13 Apr 2019 00:00:00 GMT
      DOI: 10.1093/annonc/mdz068.001
      Issue No: Vol. 30, No. Supplement_2 (2019)
       
  • 155PAssociation of immune-related adverse events (irAEs) and immunotherapy
           (IT) benefit in advanced non-small cell lung cancer (NSCLC)
    • Authors: Saavedra Serrano C; Barquín García A, Corral de la Fuente E, et al.
      Abstract: Background: IT has improved outcomes in advanced NSCLC. However, this therapy can yield significant toxicity secondary to immune activation. Several retrospective studies have reported a direct relationship between IT efficacy and the development of irAEs, in Response Rate (RR) and survival.
      PubDate: Sat, 13 Apr 2019 00:00:00 GMT
      DOI: 10.1093/annonc/mdz063.053
      Issue No: Vol. 30, No. Supplement_2 (2019)
       
  • 58PEvaluation of a care path for patients with lung tumors and co-existing
           interstitial lung disease
    • Authors: Ronden-Kianoush M; Nossent E, Dickhoff C, et al.
      Abstract: Background: Patients with lung cancer and co-existing interstitial lung disease (ILD) are at increased risk of treatment-related toxicity after both surgery and radiotherapy. A care path was implemented at our institution for patients presenting to the lung tumor board with a possible ILD, and we report on our experience using this structured approach.
      PubDate: Sat, 13 Apr 2019 00:00:00 GMT
      DOI: 10.1093/annonc/mdz066.003
      Issue No: Vol. 30, No. Supplement_2 (2019)
       
  • 51PInvasive diagnostic investigation-related complications and its impact
           on treatment initiation in lung cancer patients in a rapid access lung
           lesion clinic in regional Australia
    • Authors: McCann K; Faisal W.
      Abstract: Background: Rapid Access Lung Lesions Clinic (RALLC) is designed to expedite the diagnostic pathway of suspected lung cancer, to allow treatment in a timely fashion. Invasive investigations (i.e. bronchoscopy, EBUS biopsy, CT-guided biopsy) are the usual tools to obtain tissue for histological diagnosis and each carries a small procedure-related complications risk, which could potentially delay definitive treatment initiation until the complication resolves.
      PubDate: Sat, 13 Apr 2019 00:00:00 GMT
      DOI: 10.1093/annonc/mdz070.009
      Issue No: Vol. 30, No. Supplement_2 (2019)
       
  • 114OPotential resistance mechanisms using next generation sequencing from
           Chinese EGFR T790M+ non-small cell lung cancer patients with primary
           resistance to osimertinib: A multicenter study
    • Authors: Xu C; Wang W, Zhu Y, et al.
      Abstract: Background: Osimertinib (AZD9291) is a third generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor that has demonstrated significant clinical benefits in patients with EGFR sensitizing mutations or T790M mutation. However, approximately 5% to 15% of patients with non-small-cell lung cancer (NSCLC) with EGFR T790M mutation has primary resistance to osimertinib treatment. The underlying mechanism is unknown.
      PubDate: Sat, 13 Apr 2019 00:00:00 GMT
      DOI: 10.1093/annonc/mdz063.012
      Issue No: Vol. 30, No. Supplement_2 (2019)
       
  • 174PNSCLC stages IIa-IIIc: Tumor related IGRT yields better local control
           than kV-guidance to anatomic structures
    • Authors: Zehentmayr F; Karner J, Wurstbauer K, et al.
      Abstract: Background: The prognosis for patients with LA-NSCLC (UICC stages IIa - IIIc) is still very limited with 5-year overall survival rates (OS) of approximately 20%. The meta-analysis published by Auperin et al. published in 2010 gives evidence that improved local control (LC) translates into better OS.Concurrent chemoradiotherapy – the standard of care treatment regimen – achieves LC around 65% at two years. The aim of the current single centre analysis was a comparison of LC after tumor related image guided radiotherapy (IGRT) versus kV-IGRT to central anatomic structures.
      PubDate: Sat, 13 Apr 2019 00:00:00 GMT
      DOI: 10.1093/annonc/mdz063.072
      Issue No: Vol. 30, No. Supplement_2 (2019)
       
  • 75PThoracic ultrasound can be a trustable tool in untouchable lung nodule
           surgery
    • Authors: Zhang H.
      Abstract: Background: Localization of ground-glass opacifications (GGOs) with more than 1cm distance to the pleura are still a challenge to thoracic surgeons during video-assisted thoracoscopic surgery (VATS). Efficiency, damage avoidance, and safety are uppermost factors to be considered when choosing the location technique. Our center tested the thoracoscopic ultrasound (US) as a complementary method during VATS GGOs surgery.
      PubDate: Sat, 13 Apr 2019 00:00:00 GMT
      DOI: 10.1093/annonc/mdz064.007
      Issue No: Vol. 30, No. Supplement_2 (2019)
       
  • 12PClinicopathologic characteristics of patients with TP63 mutations in
           Chinese non-small cell lung cancer
    • Authors: Zhang Q; Xu C, Wang W, et al.
      Abstract: Background: Variation at TP63 has recently been shown to be associated with non-small cell lung cancer patients (NSCLC) in the Chinese population. There is some clinical evidence for the use of TP63 mutations as prognostic and predictive biomarker. The aim of this study is to investigate mutations and prognosis of NSCLC harboring TP63 mutations.
      PubDate: Sat, 13 Apr 2019 00:00:00 GMT
      DOI: 10.1093/annonc/mdz072.011
      Issue No: Vol. 30, No. Supplement_2 (2019)
       
  • 83OImpact of subsequent post-discontinuation immunotherapy on overall
           survival in patients with unresectable, stage III NSCLC from PACIFIC
    • Authors: Ouwens M; Darilay A, Zhang Y, et al.
      Abstract: Background: In cancer trials, pts often receive subsequent lines of anticancer Tx following progression, which, in standard ITT analyses, can lead to bias and underestimation of OS Tx effect. In the phase 3 PACIFIC trial of durvalumab vs. placebo in Stage III NSCLC pts without progression after CRT, both primary endpoints PFS and OS were met, significantly improved with durvalumab. However, after discontinuation, many pts received further anticancer Tx (41% and 54% in the durvalumab and placebo groups), including immunotherapies (IMTs), which may have influenced OS. Using the Rank Preserving Structural Failure Time (RPSFT) model, we quantified the specific impact of subsequent IMT on OS in PACIFIC.
      PubDate: Sat, 13 Apr 2019 00:00:00 GMT
      DOI: 10.1093/annonc/mdz067
      Issue No: Vol. 30, No. Supplement_2 (2019)
       
  • 154PRenal toxicity from platinum/pemetrexed and pembrolizumab in the era
           of combination therapy
    • Authors: Dumoulin D; Visser S, Cornelissen R, et al.
      Abstract: Background: Recently, the phase 3 keynote-189 trial showed that in previously untreated patients with advanced non-squamous NSCLC without targetable mutations, the progression-free and overall survival were significantly longer with addition of pembrolizumab to chemotherapy than with chemotherapy alone. Both chemotherapy and pembrolizumab can give renal toxicity, which can be a major challenge in the clinical setting.
      PubDate: Sat, 13 Apr 2019 00:00:00 GMT
      DOI: 10.1093/annonc/mdz063.052
      Issue No: Vol. 30, No. Supplement_2 (2019)
       
  • 31PDo two lungs form an integrated immune system' Learning from BALF
           examination in lung cancer
    • Authors: Domagala-Kulawik J; Skirecki T, Dziedzic D, et al.
      Abstract: Background: Bronchoalveolar lavage fluid (BALF) examination was found to be useful in the evaluation of local immune status in the site of lung cancer development. This procedure may be performed during lung cancer diagnosis and repeated during therapy. It especially concerns the majority of lung cancer cases, which are beyond the possibility of resection at recognition. However, the procedure of BAL in the lung affected by cancer is often complicated. The aim of this study was an analysis of differences in the character of immune response between the lung affected by cancer versus the opposite, ’healthy‘ lung. May BALF from the lung free of tumor serve for the characterization of local immune status'
      PubDate: Sat, 13 Apr 2019 00:00:00 GMT
      DOI: 10.1093/annonc/mdz073.010
      Issue No: Vol. 30, No. Supplement_2 (2019)
       
  • 57PNon-small cell lung carcinoma (NSCLC) patients with baseline brain
           imaging: A prospective observational study
    • Authors: Gundu N; Malik P, Khurana S, et al.
      Abstract: Background: Brain metastases in NSCLC patients is the major cause of the poor survival and quality of life. Symptomatic brain metastasis at baseline are present in 5-10% of NSCLC and over the time course about 40% patients develop brain metastasis. Screening for asymptomatic brain metastasis in advanced NSCLC is controversial. Here we present our initial experience of mandatory brain imaging of all NSCLC patients irrespective of CNS symptoms and stage.
      PubDate: Sat, 13 Apr 2019 00:00:00 GMT
      DOI: 10.1093/annonc/mdz066.002
      Issue No: Vol. 30, No. Supplement_2 (2019)
       
  • 113OEntrectinib in NTRK fusion-positive non-small cell lung cancer
           (NSCLC): Integrated analysis of patients (pts) enrolled in STARTRK-2,
           STARTRK-1 and ALKA-372-001
    • Authors: Paz-Ares L; Doebele R, Farago A, et al.
      Abstract: Background: Neurotrophic receptor tyrosine kinase (NTRK) gene fusions lead to the expression of chimeric TRK proteins with constitutively activated kinase function, conferring oncogenic potential across several tumour types. Entrectinib is a CNS-active, potent inhibitor of TRKA/B/C and ROS1. We present integrated efficacy and safety data for entrectinib in NTRK fusion-positive (NTRK-FP) solid tumours focusing on pts with NSCLC.
      PubDate: Sat, 13 Apr 2019 00:00:00 GMT
      DOI: 10.1093/annonc/mdz063.011
      Issue No: Vol. 30, No. Supplement_2 (2019)
       
  • 50PReduced-, and no-dose thin-section radiologic examinations: Comparison
           of capability for nodule detection in patients having pulmonary nodules
    • Authors: Tang W; Peng Q, Huang Y, et al.
      Abstract: Background: To evaluate the capability of pulmonary MR imaging with zero echo time (ZTE) in pulmonary nodules assessments, using low-dose computed tomography (LDCT) as the reference standard.
      PubDate: Sat, 13 Apr 2019 00:00:00 GMT
      DOI: 10.1093/annonc/mdz070.008
      Issue No: Vol. 30, No. Supplement_2 (2019)
       
  • 74PIs there any prognostic significance of the level of change in SUVmax
           after SBRT in patients with early stage NSCLC'
    • Authors: Yaprak G; Ozen A, Tugrul F, et al.
      Abstract: Background: Stereotactic body radiotherapy (SBRT) is a standard treatment for early stage non-small cell lung cancer (esNSCLC) patients who are not eligible for surgery. We aimed to evaluate the prognostic significance of the level of change in SUVmax (ΔSUVmax) between pre and post-treatment PET/CT in esNSCLC patients treated with SBRT.
      PubDate: Sat, 13 Apr 2019 00:00:00 GMT
      DOI: 10.1093/annonc/mdz064.006
      Issue No: Vol. 30, No. Supplement_2 (2019)
       
  • 133PA study evaluating the different treatment modalities for EGFR
           mutation positive advanced NSCLC patients that acquire c-MET amplification
           after EGFR TKI therapy resistant
    • Authors: Qu J; Liu L, Heng J, et al.
      Abstract: Background: c-MET amplification was one of the major important mechanisms of acquired resistance to EGFR tyrosine kinase inhibitors (TKIs). Whereas, once the patient acquired c-MET amplification combined with EGFR mutation after EGFR-TKI resistant, the most optimal treatment strategy is remains controversial. Our study proposed an optimal treatment strategy for EGFR mutant NSCLC patients who acquired c-MET amplification after EGFR TKI resistance.
      PubDate: Sat, 13 Apr 2019 00:00:00 GMT
      DOI: 10.1093/annonc/mdz063.031
      Issue No: Vol. 30, No. Supplement_2 (2019)
       
  • 11PAutophagy inhibition potentiates the anti-angiogenic property of
           multikinase inhibitor anlotinib through JAK2/STAT3/VEGFA signaling in
           non-small cell lung cancer cells
    • Authors: Liang L; Hui K, Hu C, et al.
      Abstract: Background: The efficacy and safety of multikinase inhibitor anlotinib has been confirmed in the treatment of advanced non-small cell lung cancer (NSCLC). However, the direct functional mechanisms of tumor lethality mediated by anlotinib were not fully elucidated, and the underlying mechanisms related to resistance remains largely elusive.
      PubDate: Sat, 13 Apr 2019 00:00:00 GMT
      DOI: 10.1093/annonc/mdz072.010
      Issue No: Vol. 30, No. Supplement_2 (2019)
       
  • 153PChemotherapy with immune-checkpoint inhibitors in first-line treatment
           metastatic NSCLC patients: Systematic review and literature-based
           meta-analysis
    • Authors: Addeo A; Banna G, Metro G, et al.
      Abstract: Background: Checkpoint inhibitors plus platinum-based chemotherapy have shown superiority compared to chemotherapy alone as first-line therapy in advanced non–small cell lung carcinoma (NSCLC), but little is known about the real benefit within the different PDL1 expression subgroups. Our aim was to estimate the relative benefit in term of Overall Survival (OS) and Progression-free Survival (PFS) of checkpoint inhibitors plus chemotherapy versus chemotherapy alone, overall and in subgroups defined by PDL1 expression.
      PubDate: Sat, 13 Apr 2019 00:00:00 GMT
      DOI: 10.1093/annonc/mdz063.051
      Issue No: Vol. 30, No. Supplement_2 (2019)
       
  • 56PCT image standardization is superior to larger but heterogeneous data
           for robust radiomic models
    • Authors: Vuong D; Bogowicz M, Unkelbach J, et al.
      Abstract: Background: Radiomics is a promising tool for identification of new prognostic biomarkers. Radiomic models are often based on single-institution data however multi-centric data, highly heterogeneous due to different scanning protocols, reflect better the clinical reality. Robustness studies are crucial to find features robust to e.g. scanner settings. We study if a CT radiomics overall survival (OS) model trained on multi-centric data with robust feature pre-selection can achieve a similar performance as a model on standardized data.
      PubDate: Sat, 13 Apr 2019 00:00:00 GMT
      DOI: 10.1093/annonc/mdz066.001
      Issue No: Vol. 30, No. Supplement_2 (2019)
       
  • 101TiPPACIFIC-R: First real-world study of patients with unresectable,
           stage III NSCLC treated with durvalumab after chemoradiotherapy
    • Authors: Girard N; Mornex F, Christoph D, et al.
      Abstract: Background: Approximately 30% of patients (pts) with non-small-cell lung cancer (NSCLC) are diagnosed with Stage III disease, which is often unresectable. Historically, the standard of care (SoC) has been platinum-based chemoradiotherapy (CRT), but outcomes have been poor. Durvalumab is a selective high-affinity, human IgG1 monoclonal antibody that blocks PD-L1 binding to PD-1 and CD80. In the phase 3 PACIFIC trial of durvalumab versus placebo in pts with unresectable, Stage III NSCLC without progression after concurrent CRT (cCRT), both primary endpoints progression-free survival (PFS) and overall survival (OS) were met and significantly improved with durvalumab (HR for PFS, 0.52; 95% CI 0.42–0.65; P < 0.001; HR for OS, 0.68; 99.73% CI 0.47–0.997; P = 0.0025) with similar safety between treatments (Antonia et al, NEJM 2017; 2018). Based on these findings, the PACIFIC regimen (durvalumab following CRT) is becoming the SoC. PACIFIC-Real World (PACIFIC-R) will assess if durvalumab treatment after cCRT shows similar efficacy and safety in a large, real-world population.
      PubDate: Sat, 13 Apr 2019 00:00:00 GMT
      DOI: 10.1093/annonc/mdz067.017
      Issue No: Vol. 30, No. Supplement_2 (2019)
       
  • 112OCirculating tumor (ct) DNA analysis to monitor response and resistance
           to ensartinib in patients (pts) with ALK+ non-small cell lung cancer
           (NSCLC)
    • Authors: Horn L; Whisenant J, Wakelee H, et al.
      Abstract: Background: Pts with anaplastic lymphoma kinase (ALK)-rearranged NSCLC have benefited from ALK tyrosine kinase inhibitors (TKIs); however, most pts eventually acquire resistance. Identification of resistance mutations informs subsequent therapy but has typically required invasive repeat biopsies. Here, we assessed the utility of ctDNA analysis and the ability to monitor response longitudinally and detect resistance mutations during therapy with ensartinib, a potent second-generation ALK TKI.
      PubDate: Sat, 13 Apr 2019 00:00:00 GMT
      DOI: 10.1093/annonc/mdz063.010
      Issue No: Vol. 30, No. Supplement_2 (2019)
       
  • 49PA Mendelian randomization study of the effects of Crohn’s disease
           on lung cancer
    • Authors: Liu J; Zhou H, Zhang Y, et al.
      Abstract: Background: Crohn’s disease is associated with increased lung cancer risk in observational studies, but the causality of this association is uncertain. Here we conducted a two-sample Mendelian randomisation (MR) study to examine whether Crohn’s disease is causally related to lung cancer.
      PubDate: Sat, 13 Apr 2019 00:00:00 GMT
      DOI: 10.1093/annonc/mdz070.007
      Issue No: Vol. 30, No. Supplement_2 (2019)
       
  • 173PStereotactic radiotherapy concurrent to immune or targeted therapy for
           oligometastatic NSCLC: Clinical scenarios affecting survival
    • Authors: Kroeze S; Fritz C, Kaul D, et al.
      Abstract: Background: Oligometastatic NSCLC pts. may benefit from a more aggressive treatment approach. However, the concept of “oligometastasis” is complex: e.g. limited progression or resistance of disease to systemic treatment. This study evaluated the outcome of stereotactic radiotherapy (SRT) to oligoprogressive or oligoresistant NSCLC in pts. receiving concurrent immuno- or targeted therapy.
      PubDate: Sat, 13 Apr 2019 00:00:00 GMT
      DOI: 10.1093/annonc/mdz063.071
      Issue No: Vol. 30, No. Supplement_2 (2019)
       
  • 73PUtilization rates of stereotactic body radiation therapy for the
           treatment of stage I NSCLC in three European countries
    • Authors: Damhuis R; Senan S, Khakwani A, et al.
      Abstract: Background: Stereotactic body radiation therapy (SBRT) has become increasingly accepted as a treatment for patients with inoperable early stage lung cancer. We studied the patterns of treatment utilization for stage I non-small cell lung cancer (NSCLC) in three European countries in patients diagnosed in 2015-2016.
      PubDate: Sat, 13 Apr 2019 00:00:00 GMT
      DOI: 10.1093/annonc/mdz064.005
      Issue No: Vol. 30, No. Supplement_2 (2019)
       
  • 132PNew insights into acquired resistance mechanisms to third-generation
           EGFR tyrosine kinase inhibitor therapy in lung cancer
    • Authors: Fassunke J; Heydt C, Michels S, et al.
      Abstract: Background: The emergence of acquired resistance (AR) against third-generation epidermal growth factor receptor tyrosine kinase inhibitors (TKI) remain a major clinical challenge in lung adenocarcinoma patients. Here we characterized the role of acquired resistance mechanism with a focus on inter-individual heterogeneity and co-occurring genetic aberrations. We could analyze pre- and post-treatment samples of patients treated with third-generation EGFR TKIs.
      PubDate: Sat, 13 Apr 2019 00:00:00 GMT
      DOI: 10.1093/annonc/mdz063.030
      Issue No: Vol. 30, No. Supplement_2 (2019)
       
  • 30PPrognostic significance of IGF-1 signaling pathway in patients with
           advanced non-small cell lung cancer
    • Authors: Kotsantis I; Economopoulou P, Psyrri A, et al.
      Abstract: Background: Insulin-like growth factor 1(IGF-1) signaling pathway has been suggested as an important oncogenic mediator in various malignancies, including lung cancer. In this study, we aimed to evaluate serum levels of IGF-1, IGF-2 and IGF-Binding Protein 3 (IGF-BP3) before and after chemotherapy or chemoradiotherapy treatment in patients with locally advanced/metastatic non-small cell lung cancer (NSCLC) and their potential correlation with response to therapy and patient survival.
      PubDate: Sat, 13 Apr 2019 00:00:00 GMT
      DOI: 10.1093/annonc/mdz073.009
      Issue No: Vol. 30, No. Supplement_2 (2019)
       
  • 200PImplementation of artificial intelligence (AI) for lung cancer
           clinical trial matching in a tertiary cancer center
    • Authors: Leventakos K; Helgeson J, Mansfield A, et al.
      Abstract: Background: Cognitive computing has promising potential to assist trial matching efficiency and accuracy by utilizing natural language processing and performing background analytics. The Watson for Clinical Trial Matching (CTM) cognitive system derives patient and tumor attributes from unstructured text in the electronic health record that can be matched to complex eligibility criteria in trial protocols. The Watson for CTM system was trained by Mayo Clinic subject matter experts in collaboration with IBM computer scientists/engineers and implemented in the Breast Oncology practice in July 2016. Metrics have shown an average monthly enrollment increase of 84% for breast systemic therapy trials.
      PubDate: Sat, 13 Apr 2019 00:00:00 GMT
      DOI: 10.1093/annonc/mdz065
      Issue No: Vol. 30, No. Supplement_2 (2019)
       
  • 10PThe prevalence and prognostic significance of JAK2 mutation subtypes in
           non-small cell lung cancer from Chinese populations
    • Authors: Wang W; Xu C, Zhang Q, et al.
      Abstract: Background: Although roles of JAK2 mutations in myeloproliferative neoplasms (MPN) are well established, roles of JAK2 mutations in the pathogenesis of non-small cell lung cancer (NSCLC) remain unclear. The aim of this study is to investigate mutations and prognosis of NSCLC harboring JAK2 mutations.
      PubDate: Sat, 13 Apr 2019 00:00:00 GMT
      DOI: 10.1093/annonc/mdz072.009
      Issue No: Vol. 30, No. Supplement_2 (2019)
       
  • 152PCorrelation among different KRAS alterations, genetic co-mutations and
           PD-L1 expression in patients treated with immunotherapy in metastatic
           NSCLC
    • Authors: Gianoncelli L; Spitaleri G, Passaro A, et al.
      Abstract: Background: No molecularly driven strategy against KRAS demonstrated convincing activity in clinical trials. The introduction of immune checkpoints inhibitors (IO) represents a paradigm shift in treatment of NSCLC without gene target. Considering the association with smoke, the high mutational burden, the high PDL1 expression and the abundance of T-cell infiltrating lymphocyte, KRAS mutant tumors have been considered an attractive target for IO.
      PubDate: Sat, 13 Apr 2019 00:00:00 GMT
      DOI: 10.1093/annonc/mdz063.050
      Issue No: Vol. 30, No. Supplement_2 (2019)
       
  • 48PEducation and lung cancer: A Mendelian randomisation study
    • Authors: Zhou H; Zhang Y, Liu J, et al.
      Abstract: Background: Education has been shown to be inversely associated with the incidence of lung cancer at several conventional observational studies. However, this association may be biased owing to the methodological limitations of traditional observational study-confounding, reverse causation, and measurement error. Therefore, we aimed to investigate whether more years spent in education is causally associated with risk of lung cancer through a two sample mendelian randomisation study.
      PubDate: Sat, 13 Apr 2019 00:00:00 GMT
      DOI: 10.1093/annonc/mdz070.006
      Issue No: Vol. 30, No. Supplement_2 (2019)
       
  • 111OActivity of larotrectinib in TRK fusion lung cancer
    • Authors: Drilon A; Kummar S, Moreno V, et al.
      Abstract: Background: Tropomyosin receptor kinases (TRK) fusions involving NTRK1, NTRK2 and NTRK3 genes occur in a diverse range of tumor types including lung cancer. Larotrectinib, the first FDA-approved selective TRK inhibitor, has demonstrated an overall response rate of 75% by independent central review across a broad range of tumor types (Drilon et al., NEJM 378:731-9, 2018). Here we report on the subset of lung cancer patients that have been treated with larotrectinib.
      PubDate: Sat, 13 Apr 2019 00:00:00 GMT
      DOI: 10.1093/annonc/mdz063.009
      Issue No: Vol. 30, No. Supplement_2 (2019)
       
  • 100PA new PET-CT score for locally-advanced inoperable NSCLC stage III
           patients treated with chemoradiotherapy
    • Authors: Roengvoraphoj O; Eze C, Taugner J, et al.
      Abstract: Background: FDG-PET/CT is an integral part of staging and radiation treatment planning for patients with stage III non-small cell lung cancer (NSCLC). In this study, we analysed the correlation between different PET parameters and survival in NSCLC patients treated with chemoradiotherapy (CRT).
      PubDate: Sat, 13 Apr 2019 00:00:00 GMT
      DOI: 10.1093/annonc/mdz067.016
      Issue No: Vol. 30, No. Supplement_2 (2019)
       
  • 72OMulti-centre analysis of cardiac events following radical radiotherapy
           for lung cancer
    • Authors: Sun F; Banfill K, Lilley J, et al.
      Abstract: Background: Radical radiotherapy (RRT) plays an essential role in the management of early and locally advanced lung cancer. Recent studies suggest cardiac events post radiotherapy worsen survival outcome for patients. This study aims to identify risk factors which predispose patients to cardiac events post radiotherapy.
      PubDate: Sat, 13 Apr 2019 00:00:00 GMT
      DOI: 10.1093/annonc/mdz064.004
      Issue No: Vol. 30, No. Supplement_2 (2019)
       
  • 131PUpfront whole brain radiotherapy for multiple brain metastases in
           patients with EGFR-mutant lung adenocarcinoma
    • Authors: Li C; Guo J, Zhao L, et al.
      Abstract: Background: This study aimed to evaluate the efficacy of upfront whole-brain radiotherapy (WBRT) in epidermal growth factor receptor (EGFR)-mutant lung adenocarcinoma with multiple brain metastases (BM).
      PubDate: Sat, 13 Apr 2019 00:00:00 GMT
      DOI: 10.1093/annonc/mdz063.029
      Issue No: Vol. 30, No. Supplement_2 (2019)
       
  • 210TiPEvaluation of safety and efficacy of minocycline combined with
           tyrosine kinase inhibitors in patients of EGFR mutated metastatic lung
           cancer
    • Authors: Thottian A; Babu G, Dasappa L, et al.
      Abstract: Background: Tyrosine Kinase Inhibitors (TKI) are used in the first line management of metastatic Non-Small cell lung cancer in the presence of EGFR activating driver mutations. Skin rash is one of the most common side effects associated with the use of TKIs and Minocycline is recommended for prophylaxis and treatment of TKI induced skin rash. An exploratory analysis of a Phase III study evaluating the role of Minocycline with regard to skin rash showed a trend toward improved survival in such patients. This finding can be backed by appropriate biologic rationale as Minocycline has been shown to inhibit PARP-1 in in-vitro studies and EGFR mutated lung cancers are deficient in BRCA1 leading to a synthetic lethality in tumor cells exposed to both these drugs. This study is intended to assess the safety and efficacy of minocycline in patients of metastatic Non-Small Cell Lung cancer treated with a combination of TKIs and Minocycline.
      PubDate: Sat, 13 Apr 2019 00:00:00 GMT
      DOI: 10.1093/annonc/mdz065.010
      Issue No: Vol. 30, No. Supplement_2 (2019)
       
  • 151PSafety and tolerability of pembrolizumab or placebo plus pemetrexed
           and platinum as first-line therapy in Japanese patients (PTS) with
           metastatic non-squamous non-small cell lung cancer (NSCLC) enrolled in the
           phase III KEYNOTE-189 study
    • Authors: Horinouchi H; Nogami N, Saka H, et al.
      Abstract: Background: The global, randomized, double-blind, phase 3 KEYNOTE-189 study (NCT02578680) showed significantly improved OS and PFS with pembrolizumab (pembro) + pemetrexed (pem) + platinum compared with placebo + pem + platinum with a manageable safety profile in pts with previously untreated metastatic nonsquamous NSCLC without targetable EGFR/ALK aberrations . We present safety and tolerability data from Japanese pts enrolled in KEYNOTE-189.
      PubDate: Sat, 13 Apr 2019 00:00:00 GMT
      DOI: 10.1093/annonc/mdz063.049
      Issue No: Vol. 30, No. Supplement_2 (2019)
       
  • 9PClinical validation of an NGS-based assay for detecting multiple genomic
           alterations in Chinese patients with non-small cell lung cancer
    • Authors: Ge H; Chen X, Ruan L, et al.
      Abstract: Background: Patients with non-small cell lung cancer (NSCLC) often harbors driver mutations in multiple oncogenes, including EGFR, KRAS, ALK, ROS1, BRAF, HER2, RET, etc. Driver genetic alterations are used as predictive biomarkers for molecular targeted therapies. Therefore, identifying mutations in oncogenes and tailoring therapy accordingly become a standard in clinical cancer management. A genetic testing assay based on next-generation sequencing (NGS) technology, named AmoyDx Essential NGS Panel, has been developed for multiplexed and targeted deep sequencing of variants in 10 driver genes. Clinical validation was conducted in the present study.
      PubDate: Sat, 13 Apr 2019 00:00:00 GMT
      DOI: 10.1093/annonc/mdz072.008
      Issue No: Vol. 30, No. Supplement_2 (2019)
       
  • 47PTreatment (Tx) patterns and overall survival (OS) in patients (pts)
           with NSCLC in Sweden: A SCAN-LEAF study analysis from the I-O Optimise
           initiative
    • Authors: Ekman S; Sørensen J, Brustugun O, et al.
      Abstract: Background: As part of I-O Optimise, a multinational research platform providing real-world insights into the management of lung cancers, the SCAN-LEAF study aims to describe the epidemiology, clinical care and outcomes for pts with NSCLC in Scandinavia. We report initial Tx and OS for pts with NSCLC prior to the availability of immunotherapies in Sweden.
      PubDate: Sat, 13 Apr 2019 00:00:00 GMT
      DOI: 10.1093/annonc/mdz070.005
      Issue No: Vol. 30, No. Supplement_2 (2019)
       
  • 110OPlasma circulating tumor DNA analysis (ctDNA) for molecular alteration
           detection in advanced non-small cell lung cancer (NSCLC) patients (pts)
           with isolated central nervous system (CNS) metastases (mts)
    • Authors: Aldea M; Hendriks L, Mezquita L, et al.
      Abstract: Background: In advanced NSCLC, ctDNA is an emerging tool in molecular profile testing at diagnosis and at resistance to targeted therapies. However, for CNS limited mts, ctDNA might have a reduced accuracy because of low concentrations. Aim: to assess feasibility of ctDNA in NSCLC with isolated CNS disease/progression (PD) (iCNS).
      PubDate: Sat, 13 Apr 2019 00:00:00 GMT
      DOI: 10.1093/annonc/mdz063.008
      Issue No: Vol. 30, No. Supplement_2 (2019)
       
  • 99PEfficacy and safety of adjuvant chemotherapy in lung cancer: Real-world
           evidence
    • Authors: Roitberg F; Neffá M, Bonadio R, et al.
      Abstract: Background: Platinum-based adjuvant chemotherapy (CT) improves survival in surgically resected non-small-cell lung cancer (NSCLC) patients (pts). However, cisplatin and vinorelbine (PV), the most studied regimen, is often associated with increased rates of grade 3-4 toxicities. We aimed to study the efficacy and safety of adjuvant CT in NSCLC pts in a real-world scenario.
      PubDate: Sat, 13 Apr 2019 00:00:00 GMT
      DOI: 10.1093/annonc/mdz067.015
      Issue No: Vol. 30, No. Supplement_2 (2019)
       
  • 172PA multi-center, randomized, double-blind, parallel, two-group phase
           III clinical study on the efficacy and safety of QL1101 or bevacizumab in
           combination with paclitaxel and carboplatin in the first-line treatment of
           non-squamous non-small cell lung cancer
    • Authors: Han B; Li K, Chu T, et al.
      Abstract: Background: QL1101 is a biosimilar molecule of bevacizumab (BEV,Avastin®) which is a monoclonal antibody (mAb) that binds and inhibits vascular endothelial growth factor (VEGF). The main purpose of the study is to evaluate whether the effectiveness of QL1101 is equivalent to that of Avastin®; the secondary purpose is to estimate the safety and immunogenicity.
      PubDate: Sat, 13 Apr 2019 00:00:00 GMT
      DOI: 10.1093/annonc/mdz063.070
      Issue No: Vol. 30, No. Supplement_2 (2019)
       
  • 29PPretreatment T790M mutation detection by ultrasensitive PCR assay as
           predictor of efficacy in non-small lung cancer (NSCLC) patients treated
           with 1st or 2nd generation EGFR tyrosine kinase inhibitors (TKIs)
    • Authors: Juan Vidal O; Simarro J, Lorente Estelles D, et al.
      Abstract: Background: T790M mutation detection previos to 1st/2nd generation EGFR TKIs treatmentis rare by conventional methods (1-8%), although PCR ultrasensitive methods increase their prevalence to 34-80%. The aim of the study is to evaluate the presence of T790M mutations by 2 different ultrasensitive assays and their impact efficacy.
      PubDate: Sat, 13 Apr 2019 00:00:00 GMT
      DOI: 10.1093/annonc/mdz073.008
      Issue No: Vol. 30, No. Supplement_2 (2019)
       
  • 130PRelationship of clinicopathological characteristics, EGFR genotyping
           and prognosis in non-small cell lung cancer patients with malignant
           pleural effusion
    • Authors: Zhang J; Zhou Z, Su Y, et al.
      Abstract: Background: To investigate the relationship of the clinical characteristics, EGFR genotyping and prognostic factors of malignant pleural effusion associated with non-small cell lung cancer (NSCLC).
      PubDate: Sat, 13 Apr 2019 00:00:00 GMT
      DOI: 10.1093/annonc/mdz063.028
      Issue No: Vol. 30, No. Supplement_2 (2019)
       
  • 71OImpact of underlying pulmonary diseases on treatment outcomes in early
           stage non-small cell lung cancer treated with definitive radiotherapy
    • Authors: Kim H; Yoo H, Pyo H, et al.
      Abstract: Background: Current guidelines recommend definitive radiotherapy for patients with medically inoperable early stage non-small cell lung cancer (NSCLC). However, impact of underlying pulmonary diseases on survival of those patients are unclear. Especially, although the patients with COPD and lung cancer have worse prognosis than those without COPD regardless tumor stage, the impact of coexisting COPD on treatment outcome after definitive radiotherapy has not been fully investigated. Thus, we aimed to evaluate the impact of underlying chronic pulmonary disease of COPD, IPF, and CPFE on treatment outcome following definitive radiotherapy in patients with medically inoperable stage I-II NSCLC.
      PubDate: Sat, 13 Apr 2019 00:00:00 GMT
      DOI: 10.1093/annonc/mdz064.003
      Issue No: Vol. 30, No. Supplement_2 (2019)
       
  • 209PFeasibility and utility of transbronchial cryobiopsy in primary lung
           cancer: Prospective, single arm study
    • Authors: Kirita K; Udagawa H, Matsumoto S, et al.
      Abstract: Background: Transbronchial forceps biopsy (FB) is the standard diagnostic tool for primary lung cancer. Recently, we need much amount of tissues for pathological diagnosis, mutational analysis and immunohistochemistry (IHC). The aim of this study was to prospectively evaluate safety, utility for diagnosis of primary lung cancer and biomarker analysis using cryoprobe, that was new transbronchial biopsy tool.
      PubDate: Sat, 13 Apr 2019 00:00:00 GMT
      DOI: 10.1093/annonc/mdz065.009
      Issue No: Vol. 30, No. Supplement_2 (2019)
       
  • 150PCharacterization of patients with metastatic non-small cell lung
           cancer obtaining long term benefit from immunotherapy
    • Authors: Galli G; Proto C, Signorelli D, et al.
      Abstract: Background: The indications of Immunotherapy (IO) for metastatic Non Small Cell Lung Cancer (mNSCLC) are broadening. Although different studies have proved the efficacy of IO in this setting, only a minority of patients (pts) gains advantage from IO and predictive variables of Long Term Benefit (LTB) are incompletely understood.
      PubDate: Sat, 13 Apr 2019 00:00:00 GMT
      DOI: 10.1093/annonc/mdz063.048
      Issue No: Vol. 30, No. Supplement_2 (2019)
       
  • 8PRole of chemokines in resectable non-small cell lung cancer (NSCLC)
    • Authors: Drosslerová M; Šterclová M, Vašáková M, et al.
      Abstract: Background: Complex network of chemokines is a part of immune reaction targeted against tumor cells. Chemokines influence cancer growth. It is not clear whether the concentrations of chemokines at the time of diagnosis of NSCLC reflect extent of the disease. Aim: To compare chemokine concentrations (CCL2, CCL8, CXCL12) in plasma of patients with resectable NSCLC to those without cancer. To find out whether the chemokine concentrations differ according to stage of the disease.
      PubDate: Sat, 13 Apr 2019 00:00:00 GMT
      DOI: 10.1093/annonc/mdz072.007
      Issue No: Vol. 30, No. Supplement_2 (2019)
       
  • 46PEvolution of overall survival (OS) in patients (pts) with incident
           NSCLC in Denmark and Sweden: A SCAN-LEAF study analysis from the I-O
           Optimise initiative
    • Authors: Sørensen J; Ekman S, Brustugun O, et al.
      Abstract: Background: As part of I-O Optimise, a multinational research platform providing real-world insights into the management of lung cancers, the SCAN-LEAF study aims to describe the epidemiology, clinical care, and outcomes for pts with NSCLC in Scandinavia. Here, we report temporal OS trends among pts diagnosed with incident NSCLC from 2005 to 2015 in Denmark and Sweden.
      PubDate: Sat, 13 Apr 2019 00:00:00 GMT
      DOI: 10.1093/annonc/mdz070.004
      Issue No: Vol. 30, No. Supplement_2 (2019)
       
  • 98PImplications for UK practice of the use of durvalumab in stage III
           NSCLC
    • Authors: Iqbal M; Atherton P, Macgregor C, et al.
      Abstract: Background: The PACIFIC trial showed a survival benefit in patients receiving Durvalumab after concurrent chemoradiotherapy (CRT) in stage III Non-Small Cell Lung Cancer (NSCLC). Key inclusion criteria were platinum doublet chemotherapy with no chemotherapy delivered after concurrent phase. Dose delivered was 54 - 66Gy and treatment started within 42 days of completing radiotherapy. European licence is restricted to patients with PDL1 positive tumours. Previous UK audits have shown a number of CRT regimens in routine use. We assessed the implications to UK practice of adding durvalumab after CRT.
      PubDate: Sat, 13 Apr 2019 00:00:00 GMT
      DOI: 10.1093/annonc/mdz067.014
      Issue No: Vol. 30, No. Supplement_2 (2019)
       
  • 109OEntrectinib in locally advanced or metastatic ROS1 fusion-positive
           non-small cell lung cancer (NSCLC): Integrated analysis of ALKA-372-001,
           STARTRK-1 and STARTRK-2
    • Authors: Barlesi F; Drilon A, Braud F, et al.
      Abstract: Background: Entrectinib is a potent ROS1 inhibitor (as well as TRKA/B/C), designed to effectively penetrate the central nervous system (CNS); brain metastases are common in patients (pts) with advanced ROS1 fusion-positive NSCLC. Entrectinib achieves therapeutic levels in the CNS with antitumour activity in multiple intracranial tumour models. We present updated integrated safety and efficacy data from three Phase 1/2 entrectinib studies (ALKA-372-001 [EudraCT 2012-000148-88], STARTRK-1 [NCT02097810], STARTRK-2 [NCT02568267]) in pts with locally advanced/metastatic ROS1 fusion-positive NSCLC.
      PubDate: Sat, 13 Apr 2019 00:00:00 GMT
      DOI: 10.1093/annonc/mdz063.007
      Issue No: Vol. 30, No. Supplement_2 (2019)
       
  • 171PPrevious exposure to bevacizumab indicated inferior benefits from
           PD-1/PD-L1 inhibitors in nonsquamous NSCLC
    • Authors: Zhou F; Pan Y, Zhou C.
      Abstract: Background: Bevacizumab is known to enhance the effects of immunotherapy. The landmark IMPOWER150 has demonstrated that the addition of atezolizumab to bevacizumab plus chemotherapy significantly improved survival outcomes among patients with metastatic nonsquamous NSCLC. However, the impact of previous use of bevacizumab on the efficacy of PD-1/PD-L1 inhibitors remained unclear.
      PubDate: Sat, 13 Apr 2019 00:00:00 GMT
      DOI: 10.1093/annonc/mdz063.069
      Issue No: Vol. 30, No. Supplement_2 (2019)
       
  • 28PApplicability of ctDNA at diagnosis and during the monitoring of
           EGFR-mutated patients
    • Authors: Calabuig Fariñas S; Blasco A, Durendez-Saez E, et al.
      Abstract: Background: Identification of activating mutations in the EGFR enabled to change the therapeutic approach for NSCLC patients as therapeutic targets. Liquid biopsy is a new option for analysis of biomarkers with valuable prognostic and predictive information, allowing the detection of EGFR mutations with a reproducible and minimally invasive approach. The aim of this study was to correlate EGFR mutational status in ctDNA at diagnosis and follow-up of NSCLC patients as a complementary/alternative to tissue-based molecular profiling.
      PubDate: Sat, 13 Apr 2019 00:00:00 GMT
      DOI: 10.1093/annonc/mdz073.007
      Issue No: Vol. 30, No. Supplement_2 (2019)
       
  • 129PAnlotinib can overcome acquired resistance to EGFR-TKIs via FGFR1
           signaling in non-small cell lung cancer
    • Authors: Lian Z; Du W, Zhu J, et al.
      Abstract: Background: As a novel multitarget receptor tyrosine kinase inhibitor, anlotinib has been demonstrated to be effective in inhibition of tumor angiogenesis and growth. Interestingly, a subset of advanced non-small cell lung cancer (NSCLC) patients who are refractory to EGFR-TKIs are sensitive to anlotinib treatment, the underlying molecular mechanism remained unclear. Herein, we mainly focus on elucidating the regulatory mechanism treated with anlotinib in overcoming acquired resistance to EGFR-TKIs in NSCLC and thus may develop novel therapeutic strategies for anlotinib aiming at improving the prognosis of patients resistant to TKIs.
      PubDate: Sat, 13 Apr 2019 00:00:00 GMT
      DOI: 10.1093/annonc/mdz063.027
      Issue No: Vol. 30, No. Supplement_2 (2019)
       
  • 208PSarcopenia as prognostic factor in lung cancer patients: A systematic
           review and meta-analysis
    • Authors: Büntzel J; Heinz J, Röver C, et al.
      Abstract: Background: Sarcopenia describes the loss of skeletal muscle mass. While this condition is associated with a high mortality in cancer patients, its influence on survival is still underestimated. Here we investigate the impact of sarcopenia on the prognosis of lung cancer patients.
      PubDate: Sat, 13 Apr 2019 00:00:00 GMT
      DOI: 10.1093/annonc/mdz065.008
      Issue No: Vol. 30, No. Supplement_2 (2019)
       
  • 149PEfficacy of tyrosine kinase inhibitors (TKIs) in advanced lung
           adenosquamous carcinoma
    • Authors: Hu M; Zhang B, Wang S, et al.
      Abstract: Background: Adenosquamous carcinoma (ASC) is a rare type of lung cancers, with components of both squamous carcinoma and adenocarcinoma comprising to at least 10% of the tumor. EGFR-TKIs are playing an increasingly important role in the treatment of mutation-positive lung adenocarcinoma. However, the frequency and efficacy of multi-line EGFR-TKIs for ASC patients with sensitive EGFR mutations remain unclear.
      PubDate: Sat, 13 Apr 2019 00:00:00 GMT
      DOI: 10.1093/annonc/mdz063.047
      Issue No: Vol. 30, No. Supplement_2 (2019)
       
  • 70ORadiomic-based quantitative CT analysis to predict the invasiveness of
           pure ground-glass lung adenocarcinoma
    • Authors: Xv F; Zhu W, Hu H.
      Abstract: Background: Lung cancer is till one of the leading causes of cancer-related deaths and lung adenocarcinoma is the most common type. Compared with invasive adenocarcinoma, adenocarcinoma in situ (AIS) and minimally invasive adenocarcinoma (MIA) are considered as indolent lung adenocarcinoma with good prognosis. However, AIS, MIA and even some early-stage invasive adenocarcinoma can be shown as pure ground-glass nodules on computed tomorgraphy images, which is quite difficult for clinicians to make a precise diagnosis and a suitable treatment plan. Thus, we aim to investigate the performance of radiomic-based quantitative analysis on CT images in identifying invasiveness of lung adenocarcinoma manifesting as pure ground-glass nodules.
      PubDate: Sat, 13 Apr 2019 00:00:00 GMT
      DOI: 10.1093/annonc/mdz064.002
      Issue No: Vol. 30, No. Supplement_2 (2019)
       
  • 7PImmunomodulatory effects of Tumor Treating Fields (TTFields) on lung
           cancer models
    • Authors: Weinberg U; Kaynan N, Voloshin Sela T, et al.
      Abstract: Background: Tumor Treating Fields (TTFields) are a clinically approved anti-mitotic treatment modality delivered via noninvasive application of low intensity, intermediate frequency, alternating electric fields. In this study, we evaluated whether TTFields-induced cell death can be perceived as immunogenic.
      PubDate: Sat, 13 Apr 2019 00:00:00 GMT
      DOI: 10.1093/annonc/mdz072.006
      Issue No: Vol. 30, No. Supplement_2 (2019)
       
  • 97PPattern of first-site failure and salvage treatment in patients with
           inoperable stage III non-small cell lung cancer after chemoradiotherapy
    • Authors: Eze C; Taugner J, Käsmann L, et al.
      Abstract: Background: The standard of care treatment for inoperable stage III NSCLC is concurrent chemoradiotherapy (CRT) followed by consolidation with durvalumab. Loco-regional and distant recurrences remain common. Herein, we examine pattern of first-site failure and salvage treatment.
      PubDate: Sat, 13 Apr 2019 00:00:00 GMT
      DOI: 10.1093/annonc/mdz067.013
      Issue No: Vol. 30, No. Supplement_2 (2019)
       
  • 108OTreatment duration of brigatinib in patients enrolled in the
           international expanded access program (EAP)
    • Authors: Lin M; Pan X, Hou P, et al.
      Abstract: Background: Brigatinib is a next-generation anaplastic lymphoma kinase (ALK) inhibitor for the treatment of advanced ALK+ non-small cell lung cancer (NSCLC). In June 2016, the international EAP was opened to enable access to brigatinib prior to commercial launch for patients with unmet medical need, including those who had exhausted available therapies or were unable to participate in a clinical study. This retrospective analysis evaluated real-world treatment duration using brigatinib EAP shipment and discontinuation data.
      PubDate: Sat, 13 Apr 2019 00:00:00 GMT
      DOI: 10.1093/annonc/mdz063.006
      Issue No: Vol. 30, No. Supplement_2 (2019)
       
  • 170PAdvanced non-small cell lung cancer patients with low tumor mutation
           burden might derive benefit from anti-programmed cell death (PD)-1 and
           anti-programmed deathligand 1 (PD-L1) blockade
    • Authors: Nie W; Xu M, Gan L, et al.
      Abstract: Background: We aimed to investigate the association between tumor mutation burden (TMB) and survival in non-small cell lung cancer (NSCLC) patients with anti–programmed cell death (PD)-1 and anti--programmed cell deathligand 1 (PD-L1) blockade.
      PubDate: Sat, 13 Apr 2019 00:00:00 GMT
      DOI: 10.1093/annonc/mdz063.068
      Issue No: Vol. 30, No. Supplement_2 (2019)
       
  • 45PTreatment (Tx) patterns and overall survival (OS) in patients (pts)
           with stage IIIB–IV NSCLC in Portugal: An IPO-PORTO database analysis
           from the I-O Optimise initiative
    • Authors: Soares M; Antunes L, Redondo P, et al.
      Abstract: Background: Understanding Tx patterns and related outcomes in the rapidly changing NSCLC landscape informs clinical decision-making. As part of I-O Optimise, a multinational research platform providing real-world insights into the management of lung cancers, Tx patterns and OS are reported for pts with NSCLC prior to immunotherapy reimbursement in Portugal.
      PubDate: Sat, 13 Apr 2019 00:00:00 GMT
      DOI: 10.1093/annonc/mdz070.003
      Issue No: Vol. 30, No. Supplement_2 (2019)
       
  • 27PComparison of three different gene panels for determination of tumor
           mutational burden by next generation sequencing
    • Authors: Pappesch R; Heydt C, Rehker J, et al.
      Abstract: Background: The introduction of cancer immunotherapies has improved survival rates of certain groups of patients. According to first studies, that used whole exome sequencing, the accumulation of tumor neoantigens and therefore tumor mutational burden (TMB) could be used as molecular marker for prediction. In this study, large gene panel assays of different suppliers were tested on 28 DNA samples derived from formalin fixed, paraffin-embedded (FFPE) tumor tissue with regard to implementation in routine diagnostics.
      PubDate: Sat, 13 Apr 2019 00:00:00 GMT
      DOI: 10.1093/annonc/mdz073.006
      Issue No: Vol. 30, No. Supplement_2 (2019)
       
  • 207PPrimary mucinous carcinomas of the lung: Clinical characteristics and
           treatment outcomes
    • Authors: Thottian A; Babu G, Dasappa L, et al.
      Abstract: Background: Invasive mucinous carcinoma (IMA) is a distinct histopathologic variant of adenocarcinomas of lung comprising about 2 – 10%. A large proportion of IMAs carry KRAS mutations and only rarely EGFR mutations or ALK/ROS translocations, thus most cases are not amenable for targeted therapy at present. This study was conducted to elicit the unique clinico-pathological characteristics of IMA.
      PubDate: Sat, 13 Apr 2019 00:00:00 GMT
      DOI: 10.1093/annonc/mdz065.007
      Issue No: Vol. 30, No. Supplement_2 (2019)
       
  • 128PFrequency and types of EGFR mutation in Moroccan patients with
           non-small cell lung cancer
    • Authors: Sow M; El Yacoubi H, Moukafih B, et al.
      Abstract: Background: Mutations in the epidermal growth factor receptor (EGFR) gene are commonly observed in non-small-cell lung cancer (NSCLC), particularly in adenocarcinoma histology (aNSCLC). The frequency of EGFR mutations is ethnicity-dependent, with a higher proportion in Asian populations than Caucasian populations. Yet there is a lack of data of these mutations among North African patients. The aim of this study was to report the frequency and types of EGFR mutations in a group of NSCLC Moroccan patients.
      PubDate: Sat, 13 Apr 2019 00:00:00 GMT
      DOI: 10.1093/annonc/mdz063.026
      Issue No: Vol. 30, No. Supplement_2 (2019)
       
  • 148PKRAS and ERBB-family genetic alterations affect response to PD-1
           inhibitors in metastatic non-squamous NSCLC
    • Authors: Cinausero M; Laprovitera N, De Maglio G, et al.
      Abstract: Background: Programmed cell death -1 (PD-1) PD-ligand 1 (PD-L1) inhibitors represent a novel therapeutic option for advanced chemotherapy-pretreated non-small cell lung cancer (NSCLC) patients, leading to a significant improvement in median and long-term survival. However, about 50% patients do not benefit from therapy and experience rapid disease progression. PD-L1 expression and tumor mutational burden (TBM) have been proposed as biomarker of benefit to anti-PD-1/PD-L1 therapy. However, PD-L1 is not an ideal biomarker and TMB calculation is hardly obtainable for all patients. Here, we planned to test specific NSCLC genetic alterations as potential predictive factors of response to immunotherapy.
      PubDate: Sat, 13 Apr 2019 00:00:00 GMT
      DOI: 10.1093/annonc/mdz063.046
      Issue No: Vol. 30, No. Supplement_2 (2019)
       
  • 69OComprehensive profiling of genomic and TCR repertoire in localized
           stage lung adenocarcinomas from a prospective cohort study
    • Authors: Chen K; Bai J, Zhao H, et al.
      Abstract: Background: Recently, neoadjuvant targeted therapy and immunotherapy have presented a promising clinical effect for localized stage non-small cell lung cancer. However, the characteristics and relationship of genomic and immune profiling in surgical lung adenocarcinomas has been poorly delineated to date.
      PubDate: Sat, 13 Apr 2019 00:00:00 GMT
      DOI: 10.1093/annonc/mdz064.001
      Issue No: Vol. 30, No. Supplement_2 (2019)
       
  • 96PImpact of thrombocytosis and neutrophil-to-lymphocyte ratio before
           start of chemoradiotherapy on patient survival in inoperable stage III
           NSCLC
    • Authors: Hoffmann M; Taugner J, Roengvoraphoj O, et al.
      Abstract: Background: We aimed to evaluate an impact of thrombocytosis and neutrophil-to-lymphocyte ratio (NLR) before start of multimodal treatment on survival of patients with inoperable locally advanced non-small cell lung cancer (NSCLC).
      PubDate: Sat, 13 Apr 2019 00:00:00 GMT
      DOI: 10.1093/annonc/mdz067.012
      Issue No: Vol. 30, No. Supplement_2 (2019)
       
  • 107OCrizotinib in advanced ROS1-rearranged non-small cell lung cancer
           (NSCLC): Overall survival (OS) and updated safety from PROFILE 1001
    • Authors: Shaw A; Riely G, Bang Y, et al.
      Abstract: Background: In the ongoing phase 1 PROFILE 1001 study (NCT00585195), crizotinib provided a meaningful clinical benefit for patients (pts) with advanced ROS1-rearranged NSCLC, as evidenced by a high objective response rate (72%) and rapid, substantial and durable responses (median duration of response, 18 months [mo]); in addition, crizotinib was well-tolerated (Shaw, N Engl J Med, 2014). Here, we present OS results and updated safety (additional follow-up >3 years) in these pts.
      PubDate: Sat, 13 Apr 2019 00:00:00 GMT
      DOI: 10.1093/annonc/mdz063.005
      Issue No: Vol. 30, No. Supplement_2 (2019)
       
  • 169P_PRBenefit of immunotherapy (IT) in advanced non-small cell lung
           cancer (NSCLC) in elderly patients (EP)
    • Authors: Corral de la Fuente E; Barquín García A, Saavedra Serrano C, et al.
      Abstract: Background: Despite EP (aged ≥70 years) represent the majority of patients with advanced NSCLC, the efficacy and toxicity rates of IT remain poorly described, as they are under-represented in clinical trials. Furthermore, the age-related decline in the immune system might affect efficacy of IT.
      PubDate: Sat, 13 Apr 2019 00:00:00 GMT
      DOI: 10.1093/annonc/mdz063.067
      Issue No: Vol. 30, No. Supplement_2 (2019)
       
  • 6PCorrelation of epidermal growth factor receptor mutation status in
           plasma and tissue samples of patients with lung cancer
    • Authors: Son C.
      Abstract: Background: Somatic mutations of the gene encoding epidermal growth factor receptor (EGFR) are detected in approximately 30%–50% of patients with non-small cell lung cancers (NSCLC), so detection of EGFR mutation is the pivotal step of treatment in patients with advanced NSCLC. However, difficulty in obtaining sufficient tissue and bias from the heterogeneity of the tumor samples are the major obstacles. Although analyzing EGFR with circulating tumor DNA (ctDNA) in plasma is a breakthrough, accuracy is the problem in variable methods. Peptide nucleic acid (PNA) clamping-assisted fluorescence melting curve analysis (PANAMutyper®) is a novel and highly sensitive method of detecting EGFR mutation in tumor tissues. This study was designed to evaluate PANAMutyper® for detecting EGFR mutation with ctDNA of patients with lung cancer.
      PubDate: Sat, 13 Apr 2019 00:00:00 GMT
      DOI: 10.1093/annonc/mdz072.005
      Issue No: Vol. 30, No. Supplement_2 (2019)
       
  • 206PImplementation of PD-L1 analysis among patients with non-small cell
           lung cancer in a single center
    • Authors: Tsiouprou I; Tsartsianidou V, Papaemmanouil S, et al.
      Abstract: Background: Nowadays, cancer immunotherapy is rapidly evolving and monoclonal antibodies targeting the programmed death-1 receptor (PD-1) / PD ligand 1 (PD-L1) pathway have been approved for the treatment of NSCLC; however, there is lack of evidence regarding the current use of PD-L1 analysis in the everyday clinical practice.
      PubDate: Sat, 13 Apr 2019 00:00:00 GMT
      DOI: 10.1093/annonc/mdz065.006
      Issue No: Vol. 30, No. Supplement_2 (2019)
       
  • 127PObesity has an impact on the efficacy of EGFR-TKI in NSCLC patients
           harbouring EGFR mutation: A real-world study
    • Authors: Ding Z; Chen Y, Hong Y, et al.
      Abstract: Background: EGFR-TKI has become the standard-of-care therapy for advanced NSCLC harbouring EGFR mutation. However, the efficacy varies widely, suggestive of other confounding factors. Obesity is related to the etiology, morbidity, and mortality of cancer. However, its impact on the efficacy of EGFR-TKI remains unknown.
      PubDate: Sat, 13 Apr 2019 00:00:00 GMT
      DOI: 10.1093/annonc/mdz063.025
      Issue No: Vol. 30, No. Supplement_2 (2019)
       
  • 147PImpact on KRAS-subtypes and TP53 mutations on the prognostic value of
           KRAS/KEAP1 comutations in non-small cell lung cancer (NSCLC)
    • Authors: Scheffler M; Frank R, Ihle M, et al.
      Abstract: Background: Recent studies suggest a devastating impact of KEAP1 mutations on survival in systemically treated advanced NSCLC for both KRAS-comutated and KRAS-wildtype patients. KRAS G12C mutations differ in their co-mutational properties from other KRAS mutations, and TP53 mutations affect the outcome in a subset of NSCLC like ALK-positive NSCLC. We set out this analysis to determine the impact of both KRAS G12C and co-occurring TP53 mutations on the prognostic value of KRAS/KEAP1 comutations.
      PubDate: Sat, 13 Apr 2019 00:00:00 GMT
      DOI: 10.1093/annonc/mdz063.045
      Issue No: Vol. 30, No. Supplement_2 (2019)
       
  • 106OBrigatinib (BRG) vs crizotinib (CRZ) in the phase III ALTA-1L trial
    • Authors: Califano R; Hochmair M, Gridelli C, et al.
      Abstract: Background: We report results of the first interim analysis (IA) from the ALTA-1L study of BRG vs CRZ in anaplastic lymphoma kinase (ALK) inhibitor–naive, ALK-positive non–small cell lung cancer (ALK+ NSCLC; NCT02737501).
      PubDate: Sat, 13 Apr 2019 00:00:00 GMT
      DOI: 10.1093/annonc/mdz063.004
      Issue No: Vol. 30, No. Supplement_2 (2019)
       
  • 44PTemporal trends in treatment (Tx) and overall survival (OS) among
           patients (pts) with incident NSCLC in the UK: A real-oncology database
           analysis from the I-O Optimise initiative
    • Authors: Snee M; Cheeseman S, Thompson M, et al.
      Abstract: Background: As part of I-O Optimise, a multinational research platform providing real-world insights into the management of lung cancers, temporal trends for initial Tx and OS are reported for pts diagnosed with NSCLC at Leeds Teaching Hospitals Trust (LTHT), hosting one of the largest integrated cancer centres in the UK.
      PubDate: Sat, 13 Apr 2019 00:00:00 GMT
      DOI: 10.1093/annonc/mdz070.002
      Issue No: Vol. 30, No. Supplement_2 (2019)
       
  • 26PPotentialities of liquid biopsy in advanced non-small cell lung cancer
           (aNSCLC): Early evaluation of sentinel mutations in plasma and outcome of
           patients treated with immunotherapy
    • Authors: Bonanno L; Zulato E, Attili I, et al.
      Abstract: Background: The introduction of immune-checkpoint inhibitors (ICIs) in the management of aNSCLC has led to great outcome improvement, but reliable predictive biomarkers are still a need. Liquid biopsy has the potential to monitor biological effects of treatment. Aim of the study is to explore the potential predictive value of its dynamic analysis in aNSCLC treated with ICIs.
      PubDate: Sat, 13 Apr 2019 00:00:00 GMT
      DOI: 10.1093/annonc/mdz073.005
      Issue No: Vol. 30, No. Supplement_2 (2019)
       
  • 102OFinal analysis of the phase III KEYNOTE-042 study: Pembrolizumab
           (Pembro) versus platinum-based chemotherapy (Chemo) as first-line therapy
           for patients (Pts) with PD-L1–positive locally advanced/metastatic NSCLC
           
    • Authors: Mok T; Wu Y, Kudaba I, et al.
      Abstract: Background: Pembro significantly improved OS vs chemo as first-line therapy in pts with PD-L1–positive locally advanced/metastatic NSCLC without EGFR/ALK alterations after median follow-up of 12.8 mo based on interim analysis of KEYNOTE-042 (NCT02220894). We present the final protocol-specified analysis with an additional 6 mo of follow-up.
      PubDate: Sat, 13 Apr 2019 00:00:00 GMT
      DOI: 10.1093/annonc/mdz063
      Issue No: Vol. 30, No. Supplement_2 (2019)
       
  • 168PDynamic changes of patelet-to-lymphocyte ratio predict efficacy of
           PD-1/PD-L1 inhibitors in NSCLC
    • Authors: Zhou F; Xiong A, Zhou C.
      Abstract: Background: Baseline neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) are markers of host inflammation and have been reported as prognostic factors in advanced cancer patients, but have not been analyzed extensively in lung cancer in the era of immunotherapy, especially the dynamic changes of these markers.
      PubDate: Sat, 13 Apr 2019 00:00:00 GMT
      DOI: 10.1093/annonc/mdz063.066
      Issue No: Vol. 30, No. Supplement_2 (2019)
       
  • 95PThe role of patient performance status and its changes before and after
           completion of multimodal treatment for inoperable stage III NSCLC
    • Authors: Käsmann L; Taugner J, Eze C, et al.
      Abstract: Background: The Eastern Cooperative Oncology Group performance score (ECOG-PS) is used in clinical routine to quantify patients’ general condition. We evaluated ECOG-PS before, after and its changes in the course of chemoradiotherapy (CRT) in patients with inoperable stage III NSCLC.
      PubDate: Sat, 13 Apr 2019 00:00:00 GMT
      DOI: 10.1093/annonc/mdz067.011
      Issue No: Vol. 30, No. Supplement_2 (2019)
       
  • 5PThe circular RNA circXPO1 promotes tumor growth in lung adenocarcinoma
    • Authors: Huang Q; Qiu M.
      Abstract: Background: Circular RNAs (circRNA), a subclass of noncoding RNA characterized by covalently closed continuous loops, play emerging roles in tumorigenesis and aggressiveness. Somatic copy number variations (CNV) may drive cancer progression through both coding and noncoding transcripts. In lung adenocarcinomas, tumor stage is positively correlated with the proportion of CNV. CNV-associated circRNAs in lung cancer have rarely been reported.
      PubDate: Sat, 13 Apr 2019 00:00:00 GMT
      DOI: 10.1093/annonc/mdz072.004
      Issue No: Vol. 30, No. Supplement_2 (2019)
       
  • 126PRegional retrospective analysis of outcomes of EGFR mutated
           non-squamous non-small cell lung cancer (NSCLC) patients in West Yorkshire
           
    • Authors: Sharma D; Slevin F, Clarke K, et al.
      Abstract: Background: In the UK approximately 10% of all patients diagnosed with NSCLC harbour an Epidermal Growth Factor Receptor (EGFR) mutation. Tyrosine kinase inhibitors (TKI) have been used as first-line treatment for this group of patients since 2009. We performed a retrospective analysis of our regional cohort to assess patient outcomes and document changes in practice over the years.
      PubDate: Sat, 13 Apr 2019 00:00:00 GMT
      DOI: 10.1093/annonc/mdz063.024
      Issue No: Vol. 30, No. Supplement_2 (2019)
       
  • 205PNon-small cell lung cancer in the elderly: A retrospective study
           comparing first-line treatment with single-agent vs combination
           chemotherapy vs tyrosine kinase inhibitor
    • Authors: Cipriano É; Tavares A, Soares A, et al.
      Abstract: Background: Lung cancer has a high incidence in elderly patients. These patients are more predisposed to therapeutic toxicities, drug interactions and limitations due to physiologic alterations and comorbidities. The use of single-agent versus combination chemotherapy (ChT) as a first line treatment in this group of patients continues to be debated. The objective of this study is to characterise elderly patients diagnosed with lung cancer at our institution and evaluate overall survival (OS) in this population.
      PubDate: Sat, 13 Apr 2019 00:00:00 GMT
      DOI: 10.1093/annonc/mdz065.005
      Issue No: Vol. 30, No. Supplement_2 (2019)
       
  • 146PClinical significance of ROS1 5’ deletions detected by FISH and
           response to crizotinib
    • Authors: Dall’Olio F; Lamberti G, Capizzi E, et al.
      Abstract: Background: ROS1-rearranged non-small cell lung cancer (NSCLC) patients (pts) are eligible for crizotinib therapy. Diagnosis is based on break-apart fluorescence in situ hybridization (FISH), as for ALKrearrangements, and include 5’ deletions. We report assessment of ROS15’ deletion by FISH and next-generation sequencing (NGS) and outcome of crizotinib treatment.
      PubDate: Sat, 13 Apr 2019 00:00:00 GMT
      DOI: 10.1093/annonc/mdz063.044
      Issue No: Vol. 30, No. Supplement_2 (2019)
       
  • 167PPrognostic significance of neutrophil/lymphocyte ratio in patients
           undergoing treatment with nivolumab for recurrent non-small cell lung
           cancer
    • Authors: Rapoport B; Vorobiof D, Langenhoven L, et al.
      Abstract: Background: Neutrophil-to-lymphocyte ratio (NLR) has prognostic value in several types of cancers. We investigated the influence of NLR in patients undergoing treatment with PD-1 checkpoint inhibitors for recurrent Non-Small Cell Lung Cancer (NSCLC).
      PubDate: Sat, 13 Apr 2019 00:00:00 GMT
      DOI: 10.1093/annonc/mdz063.065
      Issue No: Vol. 30, No. Supplement_2 (2019)
       
  • 105OOsimertinib for patients (pts) with leptomeningeal metastases (LM)
           associated with EGFRm advanced NSCLC: The AURA LM study
    • Authors: Ahn M; Chiu C, Cheng Y, et al.
      Abstract: Background: Osimertinib, a 3rd-generation EGFR-TKI selective for both sensitising and EGFR T790M resistance mutations, has shown efficacy in pts with CNS metastases; encouraging activity has been reported in pts with LM at 160 mg once daily (QD) (BLOOM; NCT02228369). We report LM activity with osimertinib 80 mg QD in pts with LM from studies across the AURA program (NCT01802632; NCT02094261; NCT02442349; NCT02151981).
      PubDate: Sat, 13 Apr 2019 00:00:00 GMT
      DOI: 10.1093/annonc/mdz063.003
      Issue No: Vol. 30, No. Supplement_2 (2019)
       
  • 94PChallenges in the management of stage III non-small cell lung cancer
           (NSCLC) within multidisciplinary team (MDT): A lung cancer center
           experience
    • Authors: Harbegue K; Mejri N, El Benna H, et al.
      Abstract: Background: We aimed to report patterns of care and difficulties during the management of patients with newly diagnosed stage III NSCLC who were presented at our MDT meeting.
      PubDate: Sat, 13 Apr 2019 00:00:00 GMT
      DOI: 10.1093/annonc/mdz067.010
      Issue No: Vol. 30, No. Supplement_2 (2019)
       
  • 188TiPMetformin +/- cyclic fasting mimicking diet in combination with
           platinum-pemetrexed chemotherapy for advanced LKB1 inactive lung
           adenocarcinoma: The FAME trial
    • Authors: Galli G; Signorelli D, Vernieri C, et al.
      Abstract: Background: LKB1 inactive (LKB1i) lung adenocarcinoma (LA) has an aggressive behavior and is resistant to immunotherapy (IO). LKB1i cells are vulnerable to nutrient starvation. Based on preclinical data showing a synergy cisplatin-metformin, we hypothesized that combining platinum-based chemotherapy (CT) with metformin +/- a calorie-restricted, low-carbohydrate, low-protein diet known as Fasting Mimicking Diet (FMD) may improve the efficacy of CT in patients (pts) with LKB1i LA.
      PubDate: Sat, 13 Apr 2019 00:00:00 GMT
      DOI: 10.1093/annonc/mdz063.086
      Issue No: Vol. 30, No. Supplement_2 (2019)
       
  • 125PElderly patients treated with afatinib in clinical practice: Results
           from the prospective non-interventional study GIDEON
    • Authors: Brückl W; Laack E, Kortsik C, et al.
      Abstract: Background: Elderly patients are often underrepresented in clinical trials, leading to uncertainties in the treatment of these patients in the clinical routine.
      PubDate: Sat, 13 Apr 2019 00:00:00 GMT
      DOI: 10.1093/annonc/mdz063.023
      Issue No: Vol. 30, No. Supplement_2 (2019)
       
  • 4PCorrelation between folate receptor alpha (FRα) expression and
           clinicopathological features in lung adenocarcinoma
    • Authors: Tamura N; Fujiwara Y, Hashimoto T, et al.
      Abstract: Background: FRα is present on the cell surface, mediates its intracellular transport via receptor-mediated endocytosis, and is also involved in cell division. FRα is expressed at high levels on various cancer cells, and it is considered that FRα could be a potential therapeutic target in FRα-expressing cancers.
      PubDate: Sat, 13 Apr 2019 00:00:00 GMT
      DOI: 10.1093/annonc/mdz072.003
      Issue No: Vol. 30, No. Supplement_2 (2019)
       
  • 145PClinicopathological characteristics and outcome of advanced
           ROS1-positive non-small cell lung cancer in Asian patients
    • Authors: Kho C; Lim D, Tan D, et al.
      Abstract: Background: ROS1 rearrangement is a rare and distinct molecular subset of non-small cell lung cancer (NSCLC), sensitive to tyrosine kinase inhibitors (TKI) targeting the ROS1 kinase domain. We describe the prevalence, clinicopathological characteristics and clinical outcomes of advanced ROS1 positive NSCLC patients (pts), including concomitant mutations and brain metastases.
      PubDate: Sat, 13 Apr 2019 00:00:00 GMT
      DOI: 10.1093/annonc/mdz063.043
      Issue No: Vol. 30, No. Supplement_2 (2019)
       
  • 204PDiagnostic value of concomitant use of radial probe endobronchial
           ultrasound with guide sheath and transbronchial biopsy in lung cancer
    • Authors: Lee S; Kwak S, Park M, et al.
      Abstract: Background: Although using radial endobronchial ultrasound with guide sheath (r-EBUS-GS) has shown its diagnostic power in peripheral pulmonary lesion, its actual utility is still low due to variable diagnostic performance. To overcome its limitation, we evaluated the feasibility and efficacy of r-EBUS-GS when combined with transbronchial biopsy (TBB).
      PubDate: Sat, 13 Apr 2019 00:00:00 GMT
      DOI: 10.1093/annonc/mdz065.004
      Issue No: Vol. 30, No. Supplement_2 (2019)
       
  • 104OIMpower150: An exploratory analysis of efficacy outcomes in patients
           with EGFR mutations
    • Authors: Reck M; Jotte R, Mok T, et al.
      Abstract: Background: Atezolizumab (atezo; anti–PD-L1) inhibits PD-L1 to restore anticancer immunity; bevacizumab (bev) may enhance atezo efficacy by inhibiting VEGF immunosuppression and promoting T-cell tumour infiltration. Atezo + bev + chemotherapy (chemo) prolonged PFS and OS vs bev + CP in pts with first-line nonsquamous NSCLC in the randomised Ph III IMpower150 study, including pts with EGFR or ALK genomic alterations. The purpose of this analysis is to focus on the efficacy of atezo and/or bev with chemo in pts with EGFR mutations (EGFR-mt).
      PubDate: Sat, 13 Apr 2019 00:00:00 GMT
      DOI: 10.1093/annonc/mdz063.002
      Issue No: Vol. 30, No. Supplement_2 (2019)
       
  • 124PThe effect of proton pump inhibitors (PPI) on dacomitinib (DACO)
           pharmacokinetics and efficacy in non-small cell lung cancer (NSCLC)
           
    • Authors: Li J; Nickens D, Wilner K, et al.
      Abstract: Background: Concomitant use of PPIs has been shown to decrease DACO AUClast and Cmax by approximately 39% and 51% in a healthy volunteer study. ARCHER-1050 (A1050) was a phase 3 study to evaluate DACO as first-line treatment for patients with EGFR-positive advanced NSCLC. A considerable number of patients in A1050 used concomitant PPIs. This analysis evaluates the effects of concomitant PPI use on DACO exposure and progression free survival (PFS) in NSCLC patients treated with DACO using data from A1050.
      PubDate: Sat, 13 Apr 2019 00:00:00 GMT
      DOI: 10.1093/annonc/mdz063.022
      Issue No: Vol. 30, No. Supplement_2 (2019)
       
  • 166PCorrelation of various clinical, imaging and laboratory parameters
           with outcome in patients with metastatic non-small cell lung cancer
           (NSCLC) treated with immune checkpoint inhibitors (ICIs): Results from a
           prospective, observational, single institution study
    • Authors: Rounis K; Papadaki C, Makrakis D, et al.
      Abstract: Background: PDL1 expression in the tumor is used as a biomarker predictive of benefit from ICIs in NSCLC. We prospectively evaluated clinical, imaging and laboratory parameters to identify additional factors that could be used for patient (pt) selection.
      PubDate: Sat, 13 Apr 2019 00:00:00 GMT
      DOI: 10.1093/annonc/mdz063.064
      Issue No: Vol. 30, No. Supplement_2 (2019)
       
  • 93PHeterogeneity score in inoperable stage III non-small cell lung cancer
           patients treated with definitive chemoradiotherapy: A single centre
           analysis
    • Authors: Taugner J; Käsmann L, Eze C, et al.
      Abstract: Background: Inoperable stage-III non-small cell lung cancer (NSCLC) represents a very heterogeneous disease in terms of patient and tumor characteristics. A simple heterogeneity score may help to personlize multimodal therapy.
      PubDate: Sat, 13 Apr 2019 00:00:00 GMT
      DOI: 10.1093/annonc/mdz067.009
      Issue No: Vol. 30, No. Supplement_2 (2019)
       
  • 187TiPTumor treating fields concurrent with standard of care therapy for
           stage IV NSCLC following platinum failure: Phase III LUNAR study
    • Authors: Weinberg U; Farber O, Giladi M, et al.
      Abstract: Background: Tumor Treating Fields (TTFields), a non-invasive anti-mitotic treatment, added to temozolomide significantly extended survival in newly diagnosed glioblastoma. TTFields is eficacious in preclinical in vitro and in vivo NSCLC models. A phase I/II study [NCT00749346] of advanced NSCLC of TTFields plus pemetrexed detected no serious adverse events; median overall survival (OS) of 13.8 months. The Phase 3 LUNAR study [NCT02973789] investigates if TTFields added to immune checkpoint inhibitors or docetaxel following platinum failure will increase overall survival (OS).
      PubDate: Sat, 13 Apr 2019 00:00:00 GMT
      DOI: 10.1093/annonc/mdz063.085
      Issue No: Vol. 30, No. Supplement_2 (2019)
       
  • 43OBaseline results from a French pilot study on lung cancer screening by
           CT scan: DEP KP80
    • Authors: Leleu O; Auquier M, Chauffert B, et al.
      Abstract: Background: Lung cancer is the leading cause of cancer death worldwide. Two large randomized controlled trials (NLST,NELSON) founded a significant decrease in lung cancer mortality with an annual low dose CT screening among selected current or former smockers.While being now recommended in many countries, the French National Authority for Health claimed that conditions were not sufficient for implementation of such a screening program in France. The aims of our study were to assess the feasibility and effectiveness of a lung cancer screening pilot program with LD CT scan in a French department. We report here the results of the first screening round.
      PubDate: Sat, 13 Apr 2019 00:00:00 GMT
      DOI: 10.1093/annonc/mdz070.001
      Issue No: Vol. 30, No. Supplement_2 (2019)
       
  • 25PLung tumorspheres as a drug screening platform against cancer stem
           cells
    • Authors: Herreros Pomares A; Amado H, Calabuig Fariñas S, et al.
      Abstract: Background: Treatment resistance and metastasis are linked to cancer stem cells (CSCs). This population represents a promising target, but remains unexplored in lung cancer. The main objective of this study was to characterize lung CSCs and discover new therapeutic strategies.
      PubDate: Sat, 13 Apr 2019 00:00:00 GMT
      DOI: 10.1093/annonc/mdz073.004
      Issue No: Vol. 30, No. Supplement_2 (2019)
       
  • 203PRetrospective study about lung carcinoid: Our experience in a Spanish
           hospital
    • Authors: Cabrero D; Cruz P, de Castro J, et al.
      Abstract: Background: Pulmonary carcinoids are a very rare group of neoplasia. Typical are the most frequent ones, with earlier onset than atypical carcinoids. There is no clear relationship with smoke. Most are indolent and carcinoid syndrome is rare. In the localized disease, surgery is the best choice. In locally advanced disease, radical radiotherapy can be considered. For the metastatic disease, systemic treatment with somatostatin analogs, multi-kinase inhibitors or chemotherapy can be proposed.
      PubDate: Sat, 13 Apr 2019 00:00:00 GMT
      DOI: 10.1093/annonc/mdz065.003
      Issue No: Vol. 30, No. Supplement_2 (2019)
       
  • 144PClinical and treatment features associated with improved 5-year
           survival rate in ALK-positive lung cancer treated with ALK-TKIs
    • Authors: Passaro A; Prelaj A, Spitaleri G, et al.
      Abstract: Background: ALK rearrangement predicts for prolonged survival in pts with metastatic NSCLC treated with ALK TKIs. Long-term survival, however, remains undefined in a real-world population. The objective of this study was to determine the 5-years survival in these patients and identify clinical factors associated with OS improvement.
      PubDate: Sat, 13 Apr 2019 00:00:00 GMT
      DOI: 10.1093/annonc/mdz063.042
      Issue No: Vol. 30, No. Supplement_2 (2019)
       
  • 165PClinical benefit of anti PD-1/PD-L1 plus chemotherapy versus
           chemotherapy alone in first-line treatment in advanced non-small cell lung
           cancer: A meta-analysis
    • Authors: Landre T; Des Guetz G, Vergnenegre A, et al.
      Abstract: Background: First-line therapy for advanced non–small-cell lung cancer (NSCLC) that lacks targetable mutations is platinum-based chemotherapy. Combination of anti-PD-1/PD-L1 to chemotherapy (CT) offers a new therapeutic option for this population.
      PubDate: Sat, 13 Apr 2019 00:00:00 GMT
      DOI: 10.1093/annonc/mdz063.063
      Issue No: Vol. 30, No. Supplement_2 (2019)
       
  • 123PLong term survival analysis of osimertinib in stage IV NSCLC patients
           harbored acquired EGFR T790M mutation: A real-word study in China
    • Authors: Wang S; Han B.
      Abstract: Background: Aura studies have demonstrated the efficacy of osimertinib in advanced NSCLC patients harbored acquired EGFR T790M mutation. However, the real word data remains rare in China.
      PubDate: Sat, 13 Apr 2019 00:00:00 GMT
      DOI: 10.1093/annonc/mdz063.021
      Issue No: Vol. 30, No. Supplement_2 (2019)
       
  • 103O_PRSafety and efficacy of pembrolizumab (Pembro) monotherapy in
           elderly patients (Pts) with PD-L1–positive advanced NSCLC: Pooled
           analysis from KEYNOTE-010, -024, and -042
    • Authors: Nosaki K; Hosomi Y, Saka H, et al.
      Abstract: Background: Approximately 70% of newly-diagnosed NSCLC cases occur in the elderly, and more than half are locally advanced/metastatic. We present a pooled analysis of efficacy and safety in elderly pts (aged ≥75 y) enrolled in 3 randomized controlled trials of pembro monotherapy vs standard chemotherapy (chemo) for PD-L1–positive advanced NSCLC.
      PubDate: Sat, 13 Apr 2019 00:00:00 GMT
      DOI: 10.1093/annonc/mdz063.001
      Issue No: Vol. 30, No. Supplement_2 (2019)
       
  • 186TiPAn open-label, randomized phase III study of early switch
           maintenance vs delayed second-line nivolumab in advanced stage squamous
           non-small cell lung cancer (NSCLC) patients after standard first-line
           platinum-based chemotherapy: EDEN trial
    • Authors: Gelsomino F; Tiseo M, Boni L, et al.
      Abstract: Background: Squamous non-small cell lung cancer (Sq-NSCLC) represents 20-30% of all NSCLC with a disappointing median overall survival (OS). In the last decades, first-line chemotherapy (Ctx) for advanced Sq-NSCLC has not changed and the standard of care remains a platinum-based regimen (cisplatin or carboplatin) combined with gemcitabine, vinorelbine or taxanes for up to 4-6 cycles. In non-squamous NSCLC, maintenance therapy (MTx) by continuing pemetrexed as single-agent after induction treatment has led to a 3-months improvement in OS. On the contrary, no randomized study has shown a significant benefit from MTx in Sq-NSCLC patients (pts), yet. More recently, nivolumab has become the standard of care as second line therapy. Unfortunately, 30-40% of Sq-NSCLC pts do not have access to second-line therapy because of rapid progression and decline of performance status (PS). Nivolumab as switch MTx would represent a strategy to anticipate its use, allowing more patients to benefit from immune check-points inhibitors.
      PubDate: Sat, 13 Apr 2019 00:00:00 GMT
      DOI: 10.1093/annonc/mdz063.084
      Issue No: Vol. 30, No. Supplement_2 (2019)
       
  • 92PA prospective study on the association of dose-volume histogram
           parameters with oesophagitis, radiation pneumonitis, radiation induced
           pulmonary fibrosis after receiving chemoradiation for NSCLC
    • Authors: Bhowal S; Chatterjee K, Dey J.
      Abstract: Background: The aim of this study was to assess the relationship between pulmonary V30, age, gender, smoking history, tumor location & incidence, grade of oesophagitis, radiation pneumonitis (RP) and radiation induced pulmonary fibrosis (RIPF) (within radiotherapy portals) in NSCLC patients treated with chemoradiation.
      PubDate: Sat, 13 Apr 2019 00:00:00 GMT
      DOI: 10.1093/annonc/mdz067.008
      Issue No: Vol. 30, No. Supplement_2 (2019)
       
  • 3PNotable variation of molecular testing in metastatic lung cancer in the
           Netherlands
    • Authors: Kuijpers C; Van den Heuvel M, Overbeek L, et al.
      Abstract: Background: Adequate and timely testing for molecular alterations in NSCLC is necessary to enable treatment with tyrosine kinase inhibitors (TKI) when a certain mutation or rearrangement is present. On a nationwide basis, we aimed to assess the performance of molecular testing for EGFR and/or KRAS mutation, and ALK and ROS rearrangement in a cohort of metastatic NSCLC.
      PubDate: Sat, 13 Apr 2019 00:00:00 GMT
      DOI: 10.1093/annonc/mdz072.002
      Issue No: Vol. 30, No. Supplement_2 (2019)
       
 
 
JournalTOCs
School of Mathematical and Computer Sciences
Heriot-Watt University
Edinburgh, EH14 4AS, UK
Email: journaltocs@hw.ac.uk
Tel: +00 44 (0)131 4513762
Fax: +00 44 (0)131 4513327
 
Home (Search)
Subjects A-Z
Publishers A-Z
Customise
APIs
Your IP address: 52.55.186.225
 
About JournalTOCs
API
Help
News (blog, publications)
JournalTOCs on Twitter   JournalTOCs on Facebook

JournalTOCs © 2009-